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ABSTRACT 
 
MATILDA WRAY NICHOLAS: A Unique Memory B Cell Subset Correlates with Adverse 
Outcomes in Human SLE 
(Under the direction of Stephen H. Clarke) 
 
Systemic lupus erythematosus (SLE) is a devastating systemic autoimmune disease 
marked by the production of antinuclear autoantibodies whose etiology has both genetic and 
environmental components.  We and others have shown that CD19, a positive regulator of B 
cell receptor (BCR) signaling, is ~20% decreased on peripheral blood (PB) naïve B cells in 
>95% of SLE patients (Pts).  We have also identified an expanded subpopulation of IgG+ 
memory B cells in 25-35% of SLE Pts that display a 2-4 fold increase in CD19 expression 
(CD19hi).  SLE Pts with an expanded CD19hi population (CD19hi Pts) have a unique pattern 
of autoantibody production and increased adverse clinical outcomes, particularly end stage 
renal disease and neurological complications. CD19hi B cells have an activated phenotype, 
and sequencing analysis shows they are somatically hypermutated and antigen selected. Our 
data indicate they are most likely in G1 phase of the cell cycle and are in the early stages of 
differentiation to plasma cells. 
CD19hi cells also have a ~3 fold increase in basal levels of phosphorylated Syk 
(pSyk) and ERK1/2 (pERK1/2), suggesting that they have been recently activated.  Although 
CD19hi cells are refractory to further increases in pSyk or pERK1/2, they phosphorylate other 
intermediates similarly to healthy control B cells in response to BCR stimulation. 
iv
CXCR3 expression is >14-fold elevated in CD19hi cells, and they chemotax 
effectively towards a CXCR3 ligand, suggesting they are homing to sites of inflammation.  
Importantly, CD19hi B cells are enriched for autoreactivity compared to CD19lo B cells from 
the same patient, and a 2-fold increase in this enrichment is associated with a 100-fold 
increase in the serum autoantibody titer, suggesting these cells are precursors to autoantibody 
producing plasma cells.  Finally, CD19hi Pts are short-term or non-responders to rituximab 
treatment, indicating a need for a new therapy modality for these Pts. 
Taken together, these results suggest that dysregulation of CD19 on B cells plays a 
role in the etiology and pathogenesis of SLE, and that CD19hi cells represent an autoreactive 
memory B cell subset that plays an important role in the pathology of this disease. 
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CHAPTER 1: BACKGROUND AND INTRODUCTION 
2I. B CELLS AND THE IMMUNE SYSTEM 
The immune system is traditionally divided into two large but overlapping arms: the 
innate immune system and the adaptive immune system.  Whereas the innate immune system 
is primordial, it is none the less effective against many pathogens and is the first line of 
defense against invading organisms.  However, it is only able to detect unchanging 
components common to pathogens, but rare in the host, and does not have the ability to refine 
its actions against a specific pathogen nor generate memory against it.  The adaptive immune 
system, on the other hand, generates exquisite and flexible specificity, allowing it to target 
changing aspects of pathogens.  It is also able to generate long term memory, protecting the 
host against future infections by the same organism.  It is, however, slower to respond than 
the innate immune system, and, with its nearly limitless ability to adapt to any invader, also 
carries the risk of misdirected attack against self, or autoimmunity. 
 It is only recently that the level to which these two aspects of the immune system 
influence each other has been appreciated.  We have known for some time that features of the 
adaptive system modify and guide the innate system, such as antibodies enhancing the 
phagocytosis of pathogens by opsinization, or activating complement in immune complexes 
(ICs).  We are also beginning to understand how the innate system strongly influences the 
adaptive system.  Particular complement components, for example, are necessary for an 
efficient adaptive response against certain antigens(1-4), and toll-like receptor (TLR) ligands 
also control and direct the adaptive response(5-15). 
 Herein, I will focus on the role of B cells in the normal immune response and in 
autoimmunity.  Although antibody (Ab) production is a central role of B cells, they play 
3many other pivotal roles in the immune response.  These roles of B cells in health and disease 
will be outlined in more detail below. 
A. B Cells and the Innate Immune System 
 
Traditionally, the innate immune system consists of specific cells types and soluble 
factors.  Cell types such as epithelial cells, macrophages, polymorphonuclear leukocytes 
(PMNs, or neutrophils), and others are able to participate in the innate immune response.  
Epithelial cells can provide early warning of invading pathogens by release of chemokines, 
small molecules that direct macrophages, PMNs, and lymphocytes to the site of infection.  
These cells in turn are able to phagocytose a wide variety of pathogens and produce toxic 
products which indiscriminately kill pathogens.  They are also able to secrete cytokines—
small molecules which have specific, receptor-mediated effects on cells of the adaptive and 
innate immune systems. 
 In addition, soluble proteins, particularly complement, are key mediators of innate 
immunity and are able to mediate actions on their own (such as directly inducing lysis of 
invaders or opsinization) or to enhance the actions of other aspects of the immune system 
(such as modifying responses of cell types through complement receptors). 
 There is not a clear delineation between innate and acquired immunity, however. 
Innate immunity is needed for an efficient acquired response, and aspects of the acquired 
immune system have innate-like features.  Particularly, some subsets of B cells produce what 
is known as “natural antibody” which acts as a first line of defense against many pathogens, 
and B and T cells can respond to TLR ligands. 
 
41. Toll-like Receptors  
 
Interestingly, many epithelial and immune cells are able to recognize pathogens 
through the interaction of common pathogen-associated molecular patterns (PAMPs), such as 
lipopolysaccharide (LPS), and pattern recognition receptors (PRRs), such as toll-like 
receptors (TLRs)(16, 17).  The TLR family contains 10 members, and this group appears to 
represent the first evolved type of immune defense. TLRs are highly conserved through many 
different species from plants to vertebrates, and recognize conserved lipid, carbohydrate, 
nucleic-acid and peptide structures expressed by many pathogens(18, 19).  Many of the 
subtypes share the common MyD88 signaling pathway and ultimately exert their actions 
through the activation of ubiquitous transcription factor NF-B(16, 18, 20).  The recognition 
patterns and expression location of key TLRs is shown in Table 1.1(21-23).  Like 
complement components, these ligand-receptor interactions can influence the acquired 
immune system(7, 11, 13-15, 24).  TLRs, though useful in early defense and immune 
regulation, can also become problematic in that many also bind similar antigens derived from 
the host (Table 1.1), leading to a break in immunological tolerance(5, 9, 12, 22, 25). 
Table 1.1. Properties of Toll-like receptors. 
Receptor Location Ligand Exogenous Source 
Endogenous 
Source 
TLR1 Cell Surface Lipoproteins Bacteria n/a 
TLR2 Cell Surface Peptidoglycan et al. 
Gram-positive 
Bacteria necrotic cells 
TLR3 Intracellular dsRNA Viruses necrotic cells 
TLR4 Cell Surface LPS Gram-negative Bacteria n/a 
TLR7/8 Intracellular ssRNA Viruses dead/dying cells, snRNPs 
TLR9 Intracellular CpG-containing DNA 
Bacteria and 
Viruses 
dead/dying 
cells 
5a. B cells and TLRs 
 
B cells are among the many cells in the body expressing TLRs and responding to 
stimulation by TLR ligands.  The effects of TLR stimulation upon B cells are typically highly 
stimulatory, although they depend upon B cell differentiative state, presence of concurrent 
signaling through other receptors, and the specific ligand and receptor involved(21, 22). 
 In human B cells, somewhat variable TLRs expression has been reported(26-30).  
Most report very low expression of LPS binding TLR4 on these cells(28, 29), however, an 
alternate LPS receptor, RP105, may substitute in this case(31).  By evaluating mRNA 
transcripts, TLRs1, 7, 9, and 10 are expressed in both peripheral blood (PB) and tonsillar B 
cells(28, 29).  In tonsillar B cells, little variation in expression between naïve, germinal 
center (GC), and memory B cells was found in one study(28), but another showed 
constitutive expression only in memory B cells(26, 27).  Another showed that human naïve, 
PB B cells respond robustly to ligands for TLR1/2, 7, and 9, suggesting presence and 
functional significance of these TLRs on these cells, although indirect effects via stimulation 
of dendritic cells (DC) cannot be ruled out in this study(6).  In addition, human memory B 
cells can be induced to secrete Ab upon stimulation with the TLR9 ligand CpG(32).  A 
summary of current knowledge of TLR expression in human B cells can be found in Table 
1.2(30). 
Much more is known of the function of TLRs in murine B cells, although differences 
between these B cells and human B cells are already known.  Unlike human B cells, murine 
B cells express TLR4(10), and stimulation of these cells with LPS results in significant 
proliferation.  Of particular import is the recent finding that concurrent stimulation of a B cell 
through its BCR and a TLR, particularly TLR7 and TLR9, can induce B cell activation and 
6differentiation to an antibody secreting cell (ASC), and can break tolerance in autoreactive B 
cells(5, 9, 12, 22, 25).  This may be particularly important for B cells which recognize 
nuclear components, since these antigens are often associated with various forms of DNA or 
RNA that can stimulate TLRs. 
 
Table 1.2. Expression of TLRs on human B cells. 
Receptor Naïve/Resting Activated 
TLR1 + ++ 
TLR2-5 +/- +/- 
TLR6-7 + +++ 
TLR8 + ++ 
TLR9-10 + ++++ 
+++, strong expression; ++, moderate expression; +, 
low but detectable expression; +/- low or functionally 
controversial expression 
2. The Complement Cascade and Complement Receptors 
 
Another integral component of the innate immunity is the complement system.  The 
complement system is composed of numerous small plasma proteins which have the ability 
to bind other proteins and molecules with certain properties, such as mannose or polyanionic 
surface structures of bacteria or apoptotic cells(1, 17, 33, 34).  These proteins are 
proteolytically cleaved in complex cascades of activation, the details of which are beyond the 
scope of this dissertation. Briefly, there are three pathways for complement activation: the 
classical pathway, the mannose-binding lectin pathway, and the alternative pathway.  The 
classical pathway relies on ICs formed with IgG or IgM (IgM is particularly efficient at 
activating complement).  C1q can also directly bind certain patterns on the surface of 
7pathogens and apoptotic cells.  C1 binds to the invariant regions of the antibodies; bound C1 
cleaves C4 and C2, forming C3 convertase.  C3 convertase cleaves C3, which continues the 
cascade, forms soluble C3a fragments, which have immunological activity, and coats the 
surface of the pathogen with C3b.  This induces the cleavage of C5 which initiates formation 
of the membrane attack complex (MAC), which can directly lyse certain pathogens (Fig. 
1.1)(1, 17, 33, 34). 
 
Figure 1.1. A brief overview of the classical pathway of complement.
C3a, C4b, and C5a and some of their smaller products all act as mediators of 
inflammation.  Complement receptors (CRs) exist for many of these fragments which 
enhance responsiveness of the cells which express them(17, 35).  Complement receptors 3 
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8(CR3, or CD11b), and CR4 (CD11c) are expressed on macrophages and DCs, among others, 
and stimulate phagocytosis as well as regulating the cell response(17, 35, 36).  CR2 (CD21) 
is a positive regulator of B cell receptor (BCR) signaling, and will be discussed in more 
detail in later sections.  Its close relative, CR1 (CD35), has similar function and expression 
pattern, although it differs between mouse and man.  A brief summary of complement 
receptors, their ligands, and expression can be found in Table 1.3(17, 35).  
 
Table 1.3. Complement receptors, their ligands, function, and expression. 
Receptor Ligands Functions Expression 
CR1 
(CD35) C3b, C4b, iC3b 
Stimulates phagocytosis, 
transport of ICs 
Erythrocytes, macrophages, 
monocytes, PMNs, B cells, FDCs
CR2 
(CD21) 
C3d, iC3b, 
C3dg, EBV, et 
al 
Part of BCR co-receptor 
complex B cells and FDCs 
CR3 
(CD11b) iC3b Stimulates phagocytosis 
Macrophages, monocytes, 
PMNs, FDCs 
CR4 
(CD11b) iC3b Stimulates phagocytosis 
Macrophages, monocytes, 
PMNs, FDCs 
3. B-1 and MZ B cells and Natural Antibody 
 
As mentioned above, some subsets of B cells straddle the divide between the innate 
and acquired subparts of the immune system.  These subsets are responsible for T cell 
independent (TI) production of “natural antibody”, which is typically low-affinity, cross-
reactive, and IgM.  Natural antibody represents the bulk of IgM in circulation, and is a key 
player in protection from encapsulated bacteria, septic infections, and septic shock(37-42). 
B-1 cells may branch off early from the B cell development pathway(43) and are 
present primarily in the peritoneal and pleural cavities.  They are self-renewing and express 
9germline Ab genes(43-45).  Interestingly, autoreactive specificities appear to be positively 
selected into this subset(46-48).  They also differ from B-2 cells (non-B-1 cells, see below), 
especially Fo B cells, in their activation and differentiation properties(47, 48). 
 MZ B cells share some of the activation properties with B-1 B cells, but belong to the 
B-2 B cell subset and will be discussed in more detail below. 
B. B Cells and the Adaptive Immune System 
 
The three primary cell types of the adaptive response are T lymphocytes (T cells), B 
lymphocytes (B cells), and antigen presenting cells (APCs).  T cells, so called because they 
develop and mature in the thymus, have numerous subtypes which serve diverse functions.  
CD4+ helper T cells (Th cells) serve to regulate other cell types, and can drive the immune 
response towards either an inflammatory (Type 1, or Th1) or humoral (Type 2, Th2) biased 
response, depending on the cytokines they produce(49).  CD8+ effector T cells combat 
intracellular pathogens by killing infected host cells(49).  Finally, T regulatory cells (or T 
regs) appear to serve a vital role in maintaining tolerance to self in the periphery(50).  The 
role of Th2 CD4+ T cells in B cell activation will be discussed in slightly more detail below. 
Some non-lymphatic cells, such as dendritic cells (DCs) and stromal cells, have vital 
roles in the regulation of B and T cells.  Numerous subtypes of DCs exist, and all have 
pivotal roles in activation, modulation, and control of the immune response(51-53), and 
several subtypes directly influence B cells(51, 54, 55).  Follicular dendritic cells (FDCs), 
actually a type of stromal cell, are present in germinal centers.  These cells can influence B 
cell activation and fate through trapping of ICs and antigen and production of cytokines, and 
have a debated role in lasting B cell memory, affinity maturation and the GC response(56-
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59).  Similarly, T cell maturation and selection in the thymus is guided by specialized thymic 
stromal cells. 
B cells develop in the bone marrow and serve multiple functions in the immune 
system.  As producers of Ab, they play roles in both the adaptive and innate immune 
systems(60).  They also act as antigen presenting cells, activating T cells(61-65), and there is 
accumulating evidence they may act in more subtle, regulatory fashions, such as by 
production of pivotal cytokines(66-69). 
1. Immunoglobulins 
 
Antibodies produced by B cells are diverse in both their recognition of antigen and 
their effector function.  An antibody, or immunoglobulin (Ig), is a protein consisting of two 
identical heavy chains (H) and two identical light chains (L).  Both the H and L chains 
contain constant and variable regions.  The variable regions determine antigen specificity, 
while the constant regions confer structural stability. The constant region of the H chain (Fc) 
also determines effector function and class of Ig. 
a. Ig Subtypes 
 
There are five main classes of Ig: IgM, IgD, IgA, IgE, and IgG(70). IgM exists as a 
pentimer and is always the first Ig class generated in any given B cell.  This class makes up 
the bulk of the TI and natural antibody responses, and is particularly efficient at forming ICs 
and activating complement.  IgD is still poorly understood, appears to only exist as a surface 
molecule, and is not secreted.  IgA exists primarily as a dimer and is secreted for protection 
of mucosal surfaces.  IgE is rarely present in its free form but instead coats the surface of 
mast cells and eosinophils via Fc receptors to protect against worms and other parasites.  
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IgG dominates the secondary and long-term antibody responses to T-dependent antigens.  
Several subclasses of IgG exist, each with its own mix of effector functions.  The milieu of B 
cell activation determines which, if any, class switch will occur when exposed to antigen and 
co-stimulation. 
DNA splicing prevents multiple Ig classes from being expressed in a single cell at the 
same time.  A notable exception is the co-expression of IgM and IgD which occurs 
commonly and for unknown purpose.  Once class switch from IgM occurs, the IgM and IgD 
alleles are deleted from the genomic DNA and a single Ig class is expressed for the 
remainder of the B cell’s lifespan.  This change is made via the process of class switch 
recombination (CSR), which relies at least in part on activate-induced cytidine deaminase 
(AID)(71, 72). 
As stated above, the effector functions of the various Ig classes are determined by the 
Fc region of the H chain. Three primary mechanisms are involved: formation of multimers 
and/or active transport via Fc-specific transporters into otherwise inaccessible areas (for 
example, IgA into the mucous), activation of complement by regions in the Fc (especially by 
IgM and subclasses of IgG), and association with receptors specific for the Fc regions of 
different subclasses, or Fc receptors. Some Fc receptors are inhibitory and some are 
stimulatory, and have profound regulatory ability on cell types such as T and B cells, 
dendritic cells, macrophages, eosinophils and basophils. 
b. Generation of Ig Diversity and Specificity 
 
Diversity of antigen recognition, generated by the variable regions of the H and L 
chains, is generated in four ways; three during development and one after activation(73-76). 
The variable region of the H chain consists of three gene segments, V, D, and J, while the L 
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chain has only V and J gene segments. There are multiple copies of the genes for H and L 
chains and therefore multiple copies of each variable region which can be recombined by 
recombination activating genes 1 and 2 (RAG1 and 2)(77-79), leading to the first method of 
generating variability: combinatorial diversity(73, 76, 80). During this process, nucleotides 
can be randomly added or deleted at the junctions between these regions. This is called 
junctional diversity, and can change the reading frame of the remainder of the H or L gene 
and therefore generates a non-productive rearrangement in 2 of every 3 attempts(76, 80).  
The third process which generates diversity in the Ig repertoire is the fact that both 
the H and L chain have variable regions which combine to form the binding site of the 
antibody. Thus, a recombined H chain could have very different specificities depending on 
the L chain with which it associates(76).  
The fourth method for diversity generation, somatic hypermutation (SHM)(81-83), 
occurs in the GC and requires T cell help.  SHM, dependent largely upon on AID(72, 81-83), 
induces extensive mutation in the variable regions of Ig, allowing creation and selection of B 
cells with higher specificity for a given antigen.  This is accomplished in part via 
deamination of dC residues in the variable regions of Ig genes, followed by excision with 
uracil-DNA glycosylase (UDG) or replacement(72, 83).  The GC reaction will be discussed 
in more detail below.  
2. Central B Cell Development  
 
The BCR is what allows B cells to identify and respond to foreign antigen. It consists 
of the same two H and L chains as the antibody produced by the B cell, along with two 
signaling components, Ig and Ig. The expression of this receptor guides the development 
and differentiation of the B cell(17, 74, 84-86), and it will be discussed in more detail below. 
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B cells begin as common lymphoid progenitors in the bone marrow and differentiate 
into pro-B cells, which upregulate the B cell lineage surface marker B220 and activate RAG1 
and 2 to begin DJ rearrangement of their H chain under the control of the transcription 
factors E2A, EBF, and Pax-5(87-91).  Pax-5 in particular is vital for pre-B cell 
differentiation, absolute commitment to a B cell lineage and suppression of inappropriate 
genes(89, 92, 93).  Pre-B cells upregulate CD19, a BCR co-receptor, and proceed with V-DJ 
rearrangement.  Once the H chain is rearranged, it is expressed with a surrogate Ig L chain to 
form the pre-BCR, marking the beginning of the large pre-B cell stage(74, 85).  This stage 
determines if combinatorial and junctional diversification resulted in a functional H chain.  If 
the rearranged H chain is not functional, the cell can attempt rearrangement a second time 
with the alternate H chain allele(74, 85).  If the second rearrangement does not produce 
functional H chain, the cell undergoes apoptosis and dies (positive selection, outlined below).  
If successful, the large pre-B cell undergoes clonal expansion and proceeds to the small pre-
B cell stage, where it rearranges its L chain gene.  When the BCR containing rearranged H 
and L chains is finally expressed on the cell surface, the cell is considered an immature B 
cell, and must survive another round of positive selection(74, 85, 86). 
If a functional BCR is expressed at this stage, the immature B cell leaves the bone 
marrow and immigrates to the spleen. There, it proceeds through several transitional stages 
before becoming either a MZ or mature (Fo) B cell (discussed below).  Mature B cells which 
have not encountered their cognate antigen are called naïve B cells. 
a. Positive and Negative Selection of B Cells 
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Developing B cells are subjected to both negative and positive selection in the bone 
marrow(94, 95).  If the newly generated pre-BCR or BCR is incapable of signaling, it is 
eliminated; this constitutes positive selection, since only productive rearrangements are 
selected to continue. This mechanism occurs at the pre-B cell and immature B cell stages of 
development, and appears to require basal BCR signaling or possibly a very weak or 
particular interaction with self(75, 85, 95).  
Whereas positive selection requires a sufficient pre-BCR or BCR signal, negative 
selection aims to prevent autoreactivity by eliminating immature B cells which recognize self 
before they leave the bone marrow. Since only self antigens should be present in the milieu 
of the bone marrow, if the BCR of an immature B cell transmits too strong of a signal, it is 
triggered to undergo receptor editing, which is a secondary rearrangement of its light 
chain(96). If this fails to eliminate autoreactivity, the cell undergoes apoptosis. This 
mechanism of regulation is known as clonal deletion(85, 95).  Immature B cells that survive 
both negative and positive selection leave the bone marrow and migrate to the spleen to 
complete their differentiation(97). 
3. Peripheral Development and B Cell Subsets 
 
Newly generated immature B cells leave the bone marrow and immigrate to the 
spleen.  The spleen is broadly divided in to red pulp, where the blood is filtered and iron 
recycled, and the white pulp, where lymphocytes reside(98).  The white pulp is organized in 
sheaths around branching arterial vessels, with T cells residing largely in the periarteriolar 
lymphoid sheath (PALS), directly surrounding the arterioles.  Adjacent to the PALS, B cells 
are arranged in follicles, or B cell zones, of the white pulp(98).  Surrounding the PALS and 
follicles, dividing the red and white pulp, is the marginal zone (MZ), which contains several 
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distinct populations of macrophages, DCs, and MZ B cells(98).  Interestingly, MZ B cells are 
thought to be vital in the maintenance of the MZ and the other cell types which reside 
there(99, 100). 
a. Transitional B Cells 
 
Immature B cells immigrating from the bone marrow are directed to the follicle by 
the expression of chemokine receptors, particularly CXCR5, whose ligand, CXCL13, is 
expressed by follicular stromal cells(98, 101-103).  They then proceed through several stages 
wherein they are considered transitional B cells.  Up until recently, three subsets of 
transitional cells (T1, T2 and T3) were recognized; however, recent data suggests cells 
previously defined as the T3 subset may in fact be anergic B cells and not transitional cells at 
all(104).   
T1 and T2 B cells are defined by specific sets of surface markers, half life, location, 
and response to BCR crosslinking.  As a mechanism for elimination of anti-self specificities, 
T1 B cells are eliminated by apoptosis upon antigen encounter.  T2 cells, on the other hand, 
proliferate and mature when cognate antigen is encountered(75, 105, 106).  This additional 
phase of negative selection is a vital checkpoint in the elimination of autoreactive 
specificities which have escaped central tolerance mechanisms(107-109).   
The stage at which MZ B cells branch off and immigrate to the MZ is still unclear(74, 
75).  Although still under some debate in the field, numerous data suggest that the affinity 
displayed by the BCR determines its selection into specific subsets. Stronger signaling 
through the BCR, including that which results from weak reactivity to self, may positively 
select cells into the MZ subset, while only basal BCR signaling is required for selection of 
mature Fo B cells(110, 111). 
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b. Mature (Fo) B cells 
 
T2 B cells primarily mature into Fo B cells.  Fo B cells are responsible for mounting a 
high-affinity, long-lived antibody response, and also generate the memory response against a 
specific pathogen.  Fo B cells exist in the follicle and also recirculate in the blood, lymph, 
and lymphoid tissues(112), and have a half-life of 2-3 months(105, 113).  When Fo B cells 
encounter antigen, they proliferate, upregulate activation markers such as CD80, CD86, and 
CD40, and process and present their cognate antigen on the major histocompatibility 
complex (MHC) II, priming them for T cell help.  When appropriate T cell help is supplied, 
the GC reaction is begun.  This process will be discussed in more detail below. 
c. MZ B cells 
 
MZ B cells are so called because they reside in the marginal zone of the spleen, 
which is positioned between the red and white pulp(98).  They are therefore some of the first 
cells to come into contact with circulating antigen and ICs(37, 114), and as such are perfectly 
positioned to be early immune responders.  Indeed, MZ B cells are thought to produce the 
bulk of the early, TI response(32, 114, 115).  The TI response is important in defending 
against blood-borne infection and such pathogens as encapsulated bacteria(37) and in the 
clearance of LPS, resulting in protection from endotoxic shock(40).  In contrast to that of Fo 
B cells, the MZ B cell response is typically both short-lived and rapid; recent analysis 
indicates that they are molecularly poised to secrete antibody almost immediately after 
stimulation(116).   
In addition to the TI response, MZ cells play a role in the response to T-cell 
dependent (TD) antigens(37, 117).  They are also hyperactive compared to Fo B cells in their 
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processing and presentation of antigen and stimulation of T cells(37, 118, 119), and in their 
response to BCR crosslinking  and T cell co-stimulation(118, 120, 121). 
As mentioned above, multiple lines of evidence suggest that MZ B cells are positively 
selected by recognition of self antigen.  This may be advantageous in that it may enable 
cross-reactivity with common pathogen-derived antigens, or aid in the clearance of apoptotic 
cells which could otherwise act as self-antigen (discussed below). 
4. The B Cell Receptor 
 
Unlike the T cell receptor (TCR), which respond to processed, digested pieces of 
antigen presented by MHC complexes, B cells are able to respond to soluble antigen via the 
BCR.  Recently, however, it was shown that membrane-bound antigen was more effective in 
activating B cells(122), emphasizing a possible role for DCs in B cell activation, as will be 
discussed below. 
The first step of activation of a Fo B cell is crosslinking of the BCR by antigen (Ag).  
The degree of crosslinking directly relates to the strength of the intracellular signal generated.  
The intensity of crosslinking is dependent upon properties of the Ag.  The BCR or Ab/Ag 
interaction can be measured in two ways: affinity and avidity.  Affinity is the strength of 
interaction between a single Ag epitope and a single variable region of the Ab; the higher the 
affinity, the stronger the binding of the variable region to the epitope.  Avidity is a more 
complicated measure of the total strength of interaction between an Ab and the whole Ag or 
Ag complex at all available epitopes present, taking into account multiple antigen binding 
regions.  Therefore, an Ag or Ag complex (such as an IC) with multiple epitopes would have 
higher avidity than one with a single epitope, even though the affinity of the Ab for that 
epitope is unchanged.  For purposes of activating a Fo B cell, high avidity is most important.   
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Other properties which can affect efficiency of BCR crosslinking by Ag include 
presence of TLR ligands (described above) or complement fragments (described below) in 
the Ag complex.  Signaling through the BCR can also differ depending on a variety of 
circumstances, including differentiative state, subset, previous Ag encounter, and presence of 
co-stimulation(85, 86, 123).  Pertinent signaling will be described in the following sections. 
a. Signaling Through the BCR 
 
As mentioned above, the BCR is a membrane-bound version of the Ig currently being 
expressed in a given B cell.  It is able to signal through its association with the 
transmembrane proteins Ig and Ig, which contain immunoreceptor tyrosine-based 
activation motifs (ITAMs) in their cytoplasmic tails.  Crosslinking of the BCR induces the 
formation of the BCR signalosome, a multi-protein complex containing cytosolic and 
membrane-bound signaling intermediates(124, 125).  The signalosome initiates a 
phosphorylation cascade which perpetuates and branches, culminating in the regulation of 
key genes. 
The cascade begins with the phosphorylation of two tyrosines within the ITAM motif 
by Src-family kinases, particularly Lyn(85, 86, 125).  This phosphorylation allows 
association with and phosphorylation of other tyrosine kinases which contain SH2 domains, 
including spleen tyrosine(Y) kinase (Syk)(86, 125, 126).  Syk is a key mediator of BCR 
signaling, as syk-/- B cells are greatly impaired at both the pro- to pre-B cell and immature to 
mature transitions, where positive selection occurs(127-129).  Through its regulation of other 
intermediates, Syk is essential for many downstream effects of BCR signaling, including 
activation of the phosphatidylinositol 3-kinase (PI3K) and phospholipase C2 (PLC2)
pathways(85, 126, 130).  PLC2 in turn regulates activation of protein kinase C (PKC) and 
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the Ca2+ flux.  The PI3K pathway is needed for efficient activation of the Ser/Thr kinase Akt, 
which blocks apoptosis in the stimulated cell(85). 
Other key signaling molecules downstream of Syk in the BCR signaling pathway 
include members of the mitogen-activated protein kinase (MAPK) family, such as 
extracellular signal-regulated kinase (ERK), c-Jun NH2-terminal kinase (JNK), and p38 
MAPK.  These molecules are key regulators of cell proliferation, survival, and 
differentiation.  In addition,  BCR signaling results in activation of transcription factors, 
including nuclear factor of activated T cells (NFAT) and the ubiquitously expressed NF-
B(85).  A very simplified schematic, including the key member of the co-receptor complex, 
CD19, can be found below (Fig. 1.2). 
b. The BCR Co-Receptor Complex 
 
The BCR co-receptor complex consists of CD19, a transmembrane glycoprotein with 
signaling motifs in its cytoplasmic tail(131-133); CD81 (TAPA-1), which has a role in signal 
transduction and cell adhesion(133, 134); Leu-13, which associates with CD81 in B cells and 
other cell types(133); and CD21 (CR2), a complement receptor(34, 135).  Together, these 
molecules enhance BCR signaling through several mechanisms, the most important of which 
is thought to involve engagement of CD21 by antigen bound to complement 
components(130, 132, 133).  Complement-bound antigen, allowing efficient BCR and co-
receptor complex interaction, amplifies the signal through the BCR and elicits a 200-10,000 
fold more efficient immune response than antigen alone(1, 4, 132, 133).  It also results in 
increased antigen processing and presentation than with BCR crosslinking alone(136).  At 
least part of the ability of the co-receptor complex to amplify BCR signaling is explained by 
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the finding that crosslinking the BCR/co-receptor complex activates the stimulatory BCR 
signaling pathway without concurrent activation of the inhibitory pathway(137). 
i. CD21 
 
CD21 is a transmembrane protein with 15 or 16 short consensus repeats (SCRs) and a 
short cytoplasmic tail without known signaling motifs(39, 132, 133).  CD35 shares extensive 
homology with CD21, and, in mice, they are simply splice variants of the same gene.  In 
humans, each is encoded by a separate but closely related gene and display somewhat 
differential expression(138) as described in Table 1.2. 
CD21 is unusual in that it binds several diverse ligands, including EBV, CD23, and 
IFN-, in addition to the complement fragments iC3b, C3d,g and C3d for which it is 
named(39, 135). In mice, only binding to complement fragments has been demonstrated. All 
of these ligands bind in the SCR1 and 2 domains and induce a cellular response(135), 
indicating that binding of these ligands induces signaling. It is thought that CD19 acts as the 
signaling component for CD21, which has traditionally been thought to lack significant 
signaling motifs of its own(2, 39).  However, its transmembrane domain and cytoplasmic tail 
have recently been found to interact with intermediates which effect antigen internalization 
and processing(139).  CD21 is expressed on B lymphocytes and FDCs in mice, and on these 
cells and erythrocytes in humans. 
Co-engagement of CD21 with the BCR also increases the internalization of 
antigen(140) and expression of stable antigen-MHC II complexes on the cell surface for 
presentation of antigen to T cells(3).  Interestingly, complement-linked antigen is targeted to 
different intracellular compartments and therefore may be processed differently than antigen 
alone(141-143).  In some B cells, complement is required to present antigen from ICs to T 
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cells(41, 144).  CD21 also traps ICs on MZ B cells, which then transport and transfer them 
onto FDCs(145).  
ii. CD19 
 
CD19 is an Ig superfamily transmembrane glycoprotein expressed in B cells and 
FDCs(131-133).  The 9 tyrosine residues in its cytoplasmic domain are highly conserved in 
human, mouse, and guinea-pig, suggesting a critical role in signaling(146).  Indeed, these 
residues are phosphorylated upon crosslinking and interact with PI3K and Lyn among 
others(132, 147, 148).  CD19 has been shown to be key in the efficient PI3K-dependent 
activation of Akt(149).  Additionally, CD19 can augment the phosphorylation of the Src-
family kinases, including Lyn, via a process known as progressive amplification, resulting in 
increased phosphorylation of Syk(131, 150).  Signaling through CD19 also increases 
activation of MEK1/2, which is a kinase for ERK1/2(151).  Although CD21 is thought to be 
required to bring CD19 into the BCR signaling complex, it is clear that CD19 has signaling 
roles even in the absence of CD21, given that the phenotype of CD19 deficient mice is 
considerably more profound than that of CD21 deficient mice(132, 133, 146).  It may be that 
CD19 can somehow associate with the BCR in the absence of CD21; alternatively, some 
have proposed there may be an as of yet unidentified ligand for CD19(132, 133). 
Given these findings, it is not surprising that even small increases or decreases in 
CD19 expression can have dramatic effects on B cell development, function, and notably 
tolerance in mouse and man(152-154). This will be discussed in more detail below in the 
context of autoimmunity. 
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Figure 1.2. A simplified schematic depicting signaling through the BCR.
c. Other Molecules Which Regulate B Cells 
 
Numerous additional surface receptors modulate B cell response. The most important 
are those provided by T cell help, as described below.  In addition, B cell activation can be 
enhanced by the putative Ca2+ channel CD20(155, 156), numerous cytokines, particularly IL-
21 and BLyS(157-161), and by TLR ligands, as described above. 
B cell activation and differentiation can be also be inhibited by negative regulators, 
such as the IgG receptor FcRIIb, CD5, and CD22(162-165).  Clearly, B cells are never 
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simply “turned on” or “turned off”, but their response depends on the sum of many 
competing and overlapping signals.  
5. The B Cell Response  
 
B cells can play different roles in the immune response depending on factors such as 
their subset, activation state, the properties of antigen, the involvement of other cell types, 
and many others.  As the details of the B-1 and MZ B cell response are beyond the scope of 
this dissertation, I will focus on the typical response mounted by mature B-2 B cells.   
The response begins with engagement of the BCR by antigen.  Fo B cells are highly 
motile, scanning the lymph and blood for soluble antigen, and interacting with FDCs in 
search surface-displayed antigen(103).  One mechanism by which FDCs may acquire antigen 
is the capture of ICs containing antigen by FcRs and/or complement receptors(38, 166).  
Interestingly, MZ B cells can capture ICs, bring them to FDCs, and deposit them on their 
surface(145).  In addition, compelling new data shows that FDCs can engulf, retain and 
present intact (non-degraded) antigen to B cells on their surface, eliciting strong BCR 
signaling(122, 167, 168). 
Once the cognate antigen is encountered, signaling through the BCR “primes” the B 
cell to respond to T cell help(60, 81, 103).  The antigen is internalized, processed, and 
presented on MHCII for recognition by antigen-specific Th cells.  In addition, the B cell 
proliferates and upregulates the essential co-stimulatory molecules CD40, CD80, and CD86, 
whose roles will be discussed below.  Importantly, upregulation of the chemokine receptor 
CCR7 allows B cells to locate to the B-T cell boundary in search of T cell help(165).  If a 
cognate Th cell is found, a GC reaction begins. 
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a. B-T Cell Interactions 
 
When an activated B cell encounters an activated Th cell whose TCR recognizes the 
processed antigen it is presenting, an immunological synapse is formed between the TCR and 
the antigen-MHCII complex(60, 81, 169, 170).  This interaction is the “first signal” for 
activation of the T cell; the B cell’s “first signal” was recognition of antigen.  For efficient 
activation, it must be followed by the binding of CD40 on B cells with its ligand, CD40L 
(CD154), on T cells, without which GC formation and its downstream effects are 
blocked(171).  This interaction, together with co-stimulation through the B7 molecules CD80 
and CD86 on B cells by CD28 and CTLA-4 on Th cells, acts as the key “second signal” 
necessary for efficient B and T cell activation(60, 81, 172). 
Multiple other cell-bound and secreted factors are also key in the stimulation of B 
cells by Th cells, particularly the inducible co-stimulator (ICOS) and its ligand ICOS-L, as 
well as IL-4, IL-21, and B cell activating factor belonging to the TNF family (BAFF), also 
known as B lymphocyte stimulator (BLyS)(60, 81).  
These interactions provide activation and stimulatory signals not just to B cells, but 
also to T cells.  Among other effects, the formation of these immune synapses stop T cell 
migration but not B cell migration, and B cells can be seen “dragging” T cells after synapse 
formation in intra vital imaging studies(102).   
b. Germinal Centers 
 
The provision of T cell help results in profound clonal expansion of the B cell.  Some 
of the activated B cells form foci in the T cell zones (extrafollicular foci) and differentiate 
into short-lived antibody secreting cells (ASCs), which may class switch but do not show 
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signs of SHM(171, 173).  The remainder of the B cells proliferate to form a region of IgD-
negative cells within the primary follicle, which, once it acquires a germinal center, is termed 
a secondary follicle(60, 81).  7-10 days after initial priming, the secondary follicle polarizes 
into two regions: one near the T cell zone consisting of rapidly proliferating B cells, or 
centroblasts, and one consisting of quiescent B cells, or centrocytes.  These regions are called 
the dark and light zones, respectively, and once they form, the secondary follicle is called a 
germinal center(60, 81). 
As centroblasts divide, they also undergo SHM and CSR(60, 172, 173).  They then 
proceed as centrocytes into the light zone for selection; competition for relatively limited 
supplies of antigen and a default program for cell death account for rigorous selection at this 
point(60, 81, 172).  Cells which generate lower affinity or lose the function of their BCR die, 
whereas cells whose affinity is enhanced through this process are selected to re-enter the 
cycle or differentiate into either a long-lived plasma cell (PC) or memory cell(60, 81, 169, 
171). 
One of the key transcription factors expressed in GC B cells is Bcl-6.  In mice lacking 
Bcl-6 expression, GC cannot form(174-176).  Bcl-6 also acts as a transcriptional repressor of 
cyclin dependent kinase inhibitors, allowing the rapid proliferation of centroblasts(177, 178).  
It also inhibits B lymphocyte induced maturation protein 1 (Blimp-1), a transcription factor 
crucial for PC differentiation(174, 177).  In addition to Bcl-6, Pax-5 is important in 
maintaining the identity of GC B cells, probably in part due to is repression of X-box binding 
protein 1 (XBP-1), which is upregulated upon Fo B cell activation and required for PC 
differentiation(178-180).  Together, these proteins control the decision between exit to an 
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extrafollicular response vs. generation of memory, and their role in differentiation to PCs will 
be discussed more below. 
In addition to the role of Th cells in the GC reaction, many studies have shown that 
FDCs play a role in survival and selection of GC B cells by means of antigen held on their 
surface(181, 182) and expression of surface-bound and secreted factors, particularly 
BLyS(57, 183-187).  It was long held that the main function of CR2 on FDCs was capture of 
ICs, however, this idea was recently confounded by the finding that expression of CR2 on 
FDCs is critical, even in mice lacking any secreted Ab and therefore lacking ICs(188);  this 
may mean that CR2 has a signaling role in FDCs.  The precise role of FDCs in the GC 
reaction is still under debate(187). 
c. Plasma Cells 
 
Plasma cells are one of two main outcomes of the GC response and represent terminal 
differentiation of the B cell lineage.  They are long-lived, secrete class-switched, SHM Ab, 
and are characterized by the downregulation of B cell specific surface markers such as the 
BCR, CD19, CD20, B220, MHCII and others, with concurrent upregulation of  syndecan-1, 
or CD138(171).  Cells committed to this lineage leave the GC as pre-PC, or plasmablasts, 
since fully differentiated PC no longer respond to chemotactic signals(171).   
While the majority of plasmablasts express CXCR4, which through its interactions 
with its ligand CXCL12 direct PCs to the bone marrow (BM), a subset express CXCR3(180, 
189-191).  The CXCR3 ligands CXCL9 and 10 are expressed at sites of inflammation(192) 
and direct a subset of PCs there, where they terminally differentiate and become resident 
producers of Ab(193-196).  Once formed, PCs can persist and secrete Ab for long periods of 
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time, likely decades, depending on their environment(197).  The phenomenon of long-lived 
PCs residing in extra-lymphatic tissue is prominent in states of autoimmunity(193-195). 
As mentioned above, complex transcriptional control is involved in the differentiation 
of PCs.  In short, Pax-5 is downregulated, leading to a decrease in Bcl-6; the decrease in 
expression of these proteins relieves repression of Blimp-1, the master regulator of PC 
differentiation(171, 180). Blimp-1 in turn further represses Pax-5, Bcl-6, proliferation, and 
other B cell lineage genes, while activating XBP-1(171, 180).  Recent studies indicate that 
commitment to this lineage also requires expression of the transcription factor IRF-4, which 
acts to upregulate Blimp-1 and other PC specific genes(189).  A very simplified schematic 
depicting the interaction of these proteins can be found in Fig. 1.3(171, 180). 
 
Figure 1.3. Interactions of transcriptional regulators controlling PC differentiation.
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d. Memory B Cells 
 
The other type of effector B cell generated by the GC response is the memory B cell. 
Memory B cells are long lived and express Ig, which has, like that of PCs, undergone SHM 
and typically CSR.  In humans, they are defined as CD19+CD38- population which also 
typically, but not always, expresses CD27(197-200).  Class-switched (or IgD-) and IgM 
memory cells have been identified, both of which show SHM of their Ig(201, 202) and, in 
fact, presence of mutations in the V regions of the BCR has been the “gold standard” of 
defining a memory population(203).  Antigen-specific memory B cells can be detected for an 
impressive 60 years or longer after primary immunization(204).   
The role of persistent antigen, in various forms, in the maintenance of this population 
is debated(205, 206).  It was initially shown that the presence of antigen on the surface of 
FDCs was required for the maintenance of memory B cells(205, 207).  However, in the 
absence of secreted Ig, which precludes IC formation, memory B cells display the same 
lifespan and function as those in control mice(208).  In another experimental setting, memory 
B cells could be manipulated via a genetic switch to change BCR specificity.  In this case, 
the memory B cells with specificity for an antigen never present in the animal persisted just 
as well as memory cells of the originally induced specificity(206).  Therefore, the currently 
favored hypothesis is that that antigen is not required for maintenance of memory B 
cells(197). 
Recently, focus has shifted from the study of memory B cells as a homogenous group 
to an attempt to delineate them into distinct subsets.  Multiple lines of evidence suggest that 
memory B cell subsets with distinct functional and more subtle but detectable surface 
phenotypes exist(203).  In mice, multiple subsets of memory B cells are beginning to be 
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defined based on surface receptor expression and function(209, 210).  Emerging evidence 
suggests that this is the case in the human memory B cell pool(197-200), although specific 
markers largely remain to be elucidated.  One possible marker is Fc receptor homologue H4 
(FcRH4), which was found on a subset of largely CD27+ but class-switched and SHM B 
cells in human tonsil, although the significance of this finding is still unclear(200).  In 
addition, it has recently been shown that a small subset of peripheral memory B cells in 
humans express CXCR3, are able to chemotax towards the corresponding ligands, and that 
expression of this receptor is maintained upon differentiation to a PC(190, 211); these cells 
may represent a distinct subset of memory B cells in humans.  
Traditionally, cognate antigen and memory Th cells are thought to be required for 
activation of quiescent memory B cells(60, 191, 212).  However, some evidence exists that 
polyclonal stimuli can induce the proliferation and even differentiation of human memory B 
cells(213), particularly “bystander” T cell help (soluble cytokines), CpG(26, 213), or 
stimulation with CD27 ligand (CD70) and IL-10(214).  Overall, memory B cells appear to be 
poised to respond rapidly to activating stimuli.  In vitro, stimulation through the BCR leads 
to increased secretion of Ig by memory B cells compared to naïve B cells, and memory, but 
not naïve, B cells are able to differentiate to ASCs upon stimulation with anti-CD40, IL-2 
and IL-10 in the absence of antigen(215, 216). 
Upon stimulation, memory B cells proliferate, some replenishing the memory cell 
pool, and others differentiating into short- or long-lived PCs(60, 191, 197, 209, 216, 217).  
They also strongly upregulate B7 molecules and, unlike naïve B cells, are able to effectively 
present antigen to T cells(215).  Memory B cells retain expression of Pax-5 until their 
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reactivation and proliferation, after which those differentiating to a PC undergo the same 
transcriptional shifts as a GC B cell differentiating into a PC. 
e. Other Effector Functions of B Cells 
 
Though production of Ab is a central role of B cells, they have other pivotal roles in 
immune response and regulation.  As mentioned above, B cells can act as APCs, and in some 
autoimmune diseases, particularly SLE, arthritis, and non-obese diabetes, appear to be the 
required APC for initial T cell activation and break in tolerance (218-220). 
 B cells also have the capacity for significant production of important cytokines.  They 
have been shown to produce both Th1 and Th2 cytokines, especially IL-10, IL-6, and TNF-
(221-224).  IL-10 and IL-6 have autocrine effects on B cells in addition to their effects on 
other cell types, and promote a Th2 response; TNF- is one of the most potent cytokines, 
mediating a largely Th1 response and activating CD8+ T cells and macrophages, among 
others. 
B cells have also been shown to produce IL-2, IL-4 and IFN-, though possibly to a 
lesser extent than those listed above(225-228).  IL-2 and IFN- mediate Th1 responses, while 
IL-4 is considered a Th2 cytokine. 
Like Th cells, which can differentiate to Th1 or Th2 types to mediate a Type 1 or 
Type 2 response, B cells can become Type 1 or Type 2 B effector cells (Be1 and Be2) which 
possess many of the same traits as Th1 or Th2 cells, and can control the development of Th1 
and Th2 subtypes from naïve Th cells(229-231).  Be1 and Be2 cells produce IL-2 at nearly 
equal levels. Be1 cells produce significant quantities of IFN- and IL-12, whereas Be2 cells 
produce negligible amounts of these cytokines.  On the other hand, Be2 cells produce IL-4, 
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IL-6, and IL-10; Be1 cells produce essentially no IL-4, 4-fold less IL-6, and less than half as 
much IL-10 comparatively(230). 
Most interestingly, Be1 and Be2 cells were able to efficiently generate Th1 or Th2 
cells, respectively, from naïve CD4+ T cells, and in vivo responded by producing cytokines 
even before Th cells.  These data indicate that not only do B cells produce Type 1 and 2 
relevant cytokines themselves, but are able to effectively polarize the global response, and 
may be among the first cell types to do so(230). 
 Clearly, B cells play many roles in the innate and acquired immune systems, even 
apart from their production of Ab. 
C. Generation and Maintenance of Self-Tolerance 
 
Many mechanisms of central and peripheral tolerance via negative and positive 
selection have been outlined above, including receptor editing and clonal deletion.  There are, 
however, additional mechanisms of peripheral tolerance in particular which are crucial to 
prevention of autoreactivity.  These include anergy, block of differentiation at the pre-PC 
stage(232) and suppression by cytokines secreted by DCs and macrophages, which will be 
discussed briefly below. 
1. Anergy 
 
Anergy is a state of non-responsiveness induced by antigen encounter at an early 
differentiative stage or by chronic antigen exposure(233-236).  Generally, whereas higher 
avidity for self results in receptor editing and clonal deletion, B cells which recognize 
autoantigens with low avidity will be regulated by anergy(233). 
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Anergic B cells do not proliferate, upregulate activation markers, or secrete Ab in 
response to BCR crosslinking(235, 237).  This is due, at least in part, to dampened signaling 
through the BCR as measured by decreased phosphorylation of substrates and decreased Ca2+ 
flux(124, 238, 239).  Interestingly, although these intracellular responses to BCR 
crosslinking are diminished and altered, some are basally elevated compared to naïve B cells, 
including intracellular Ca2+ levels(104, 124, 238, 239) and ERK phosphorylation(124, 240). 
Anergic cells also have a shorter half-life than naïve B cells(241), due in part to their 
increased dependence upon BAFF for survival(242). 
 An emerging mechanism for anergy appears to be activation of Lyn and its 
downstream pathways in the absence of Syk activation(233).  Among other effects, this 
would promote the inhibitory feedback mechanisms involving the phosphatases SHP-1 and 
SHIP, blocking the Akt survival pathway and activation of NF-B by Akt and Syk(233).  
The precise mechanisms governing anergy remain to be elucidated, and many subtle 
subtypes of anergy, or varying states of “non responsiveness” may exist. 
2. Other Means of Peripheral Tolerance 
 
Despite all of the above mechanisms to eliminate or silence autoreactive B cells, 
some still persist.  Numerous additional mechanisms exist to prevent the formation of high-
affinity anti-self Ab and/or memory B cells.  Autoreactive B cells experience impaired 
selection in the GC and blocks in PC formation(243) or are excluded from the follicle 
(“follicular exclusion”)(234).  Recently a block was described for autoreactive B cells at the 
pre-PC stage, which represents regulation at the latest possible differentiative step(232).  Ab 
secretion by self-specific mature B cells can also be suppressed by DCs and macrophages 
through the secretion of soluble mediators, particularly IL-6(244). 
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T cells also play a role in preventing B cell autoimmunity; the simple lack of cognate 
anti-self T cell help can block humeral autoimmunity.  In addition, T regs can suppress B cell 
activation and Ab secretion(245). 
II. AUTOIMMUNE DISEASE 
 
With the phenomenal ability of B and T cells to generate receptors with nearly 
infinite specificity, it is not surprising that many generate receptors which recognize 
components of self.  The immune system has therefore evolved the complex and multi-
layered mechanisms described above to prevent the immune system from unleashing its 
considerable arsenal upon the host.  Given the frequency with which autoreactive B and T 
cells develop, it is a testimony to these mechanisms that so little autoimmune disease occurs. 
 In humans, autoimmune disease takes many forms.  Often, these diseases are broadly 
divided into those primarily mediated by either T cells or B cells.  Clearly, as the immune 
system is a complex, interdependent system, few if any diseases are mediated by a single cell 
type.  However, the heterogeneous family of autoimmune disorders mediated by 
autoantibody are considered to be chiefly B cell mediated (e.g., SLE), while diseases marked 
by the infiltration and destruction of tissue by T cells are considered to be chiefly T cell 
mediated (e.g., Type 1 Diabetes). Recently, a pivotal role for B cells, outside of their ability 
to produce autoantibody, has been described.  It is now clear that in some systems, B cells 
acting as APCs are responsible for the initial break of T cell tolerance(246-248). 
 A summary of autoantibody-mediated diseases can be found in Table 1.4, along with 
their common autoantibody targets(249).  Interestingly, a majority of these diseases are up to 
10 times more common in women than in men, indicating that hormonal environment may 
play a decisive role in the development of these diseases(249, 250). 
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A. Systemic Lupus Erythematosus 
 
Systemic lupus erythematosus (SLE) is a devastating, multi-system autoimmune 
disease which affects millions of people worldwide.  One of the most common autoimmune 
diseases, the prevalence of SLE in the US is approximately 1 in 2000 with an annual 
incidence of 1 in 10,000(251).  Like most autoimmune diseases, SLE affects women much 
more often than men, at a ratio of about 10:1(252), and exposure to additional estrogen, such 
as through oral contraceptive use, can double risk of developing the disease(249), 
highlighting a pivotal role for this hormone in disease development.  Additionally, ethnic 
groups are effected three times more often than Caucasians(253).  The pathology of SLE is 
due to production of autoantibodies, primarily anti-nuclear antibodies (ANA), which are 
found in 95% of patients(254).  The interaction of these autoantibodies with their 
corresponding self antigen leads to formation of ICs, which are deposited in vessels and 
kidneys. This deposition activates the complement cascade within tissues, causing extensive 
damage.  
1. Autoantibodies in SLE 
 
Although various types of ANA exist in other autoimmune diseases and even at low 
levels in healthy individuals, two are relatively specific for SLE: anti-dsDNA antibodies and 
anti-Smith (Sm) antibodies.  Sm is a small nuclear ribonucleoprotein (snRNP) which is part 
of an RNA splicosome complex.  While anti-dsDNA antibodies are sometimes found in low 
amounts in serum from non-SLE patients, a greatly elevated titer is considered one of the 
diagnostic criteria for SLE (American College of Rheumatology SLEDAI), with a sensitivity 
of 95%.  Anti-Sm antibodies, on the other hand, are 99% specific for SLE and are considered 
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to be an indicator of more active disease and poorer prognosis.  While they are seen in only 
about 30% of SLE patients, they are not seen in health or other disease states(255).  
 
The targeting of intracellular components by autoantibodies in SLE has long been 
considered a mystery, but recent data indicates that features of apoptosis may explain the 
formation of ANA.  During apoptosis, numerous intracellular proteins, including nuclear 
components, are exposed on the surface of apoptotic blebs(256-258).  Many labs have 
accumulated evidence that, in fact, apoptotic cells act as the stimulating antigen in SLE; 
apoptotic cell immunization activates autoreactive B cells and triggers autoantibody 
production, and defects in apoptotic cell clearance correlate with development of 
autoantibodies(258-261).  Why these normally tolerogenic dying cells stimulate autoantibody 
production in lupus-prone individuals remains unclear, but is an area of active investigation. 
2. Etiology of SLE 
 
Current data strongly suggest that genetic factors predispose to SLE, but alone are not 
sufficient to trigger the disease; a gene-environment interaction is necessary(262).  The 
Table 1.4. Autoantibodies in human rheumatologic diseases 
Disease Autoantibody specificity 
Myasthenia gravis Nicotinic acetylcholine receptor 
Antiphospholipid syndrome Phospholipid-2-glycoprotein 1 complex 
Insulin-resistant diabetes mellitus Insulin receptor 
Pernicious anemia Intrinsic factor 
Graves’ disease TSH receptor 
Wegener’s granulomatosis Proteinase-3 (ANCA) 
Pemphigus vulgaris Epidermal cadherin and desmoglein 3 
Goodpasture’s syndrome Collagen IV 
Systemic lupus erythematosus (SLE) dsDNA, snRNPs 
Rheumatoid arthritis (RA) Ig 
Autoimmune thrombocytopenic purpura Platelets 
Autoimmune hemolytic anemia Rh antigens, I antigen 
Hashimoto’s thyroiditis Thyroid peroxidase, thyroglobulin 
36
complexity of interaction between genes and environmental exposures has made it difficult to 
study.  With the advent of transgenic and knockout mice, a better understanding of this 
interplay has become possible.  Specific genes have been linked to SLE in humans and in 
mice, as have various environmental exposures(263, 264).  Although no single gene always 
results in lupus, abnormalities in certain genes, such as those encoding HLA-DR2(264), FcR
receptors(265, 266) and proteins of the complement system(253, 265) are associated with 
lupus in mice and man.  Likewise, environmental exposures have been implicated in both the 
development and progression of the disease; silica(267, 268), heavy metals(262, 269, 270), 
chemicals(270, 271), certain viruses, especially EBV(272, 273), radiation(274, 275), and 
ultraviolet (UV) radiation exposure(276, 277) are among those most often linked to onset or 
relapse of SLE.  Clearly, both genetic and environmental factors are important in the 
development of lupus; monozygotic twin concordance for SLE is only about 25-50%(255, 
278), and no single environmental agent results in disease in all, or even most, individuals. 
The complement components C1q, C2, and C4 are all intimately linked to 
development of SLE in humans(253, 278-280).  Of all known genetic predispositions, 
deficiency in complement C1q or C4 have the strongest associations with the development of 
SLE(249).  In humans, there are two genes for C4: C4A and C4B.  Although deficiency in 
both genes, resulting in a complete lack of C4, is very rare, it is estimated that S75% of these 
individuals develop SLE(281).  Heterozygous deficiency in either C4A or C4B, resulting in 
decreased C4 levels, is much more common and is also strongly associated with the 
development of SLE, occurring in 40-60% of SLE patients(282). 
There is accumulating evidence that CD21 may be important in human SLE as well. 
A population of CD21 low B lymphocytes is present in the peripheral blood of SLE 
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patients(283).  When B cells are activated, CD21 is shed from the cell surface in what 
appears to be regulated intramembrane proteolysis(284).  SLE patients have decreased levels 
of the shed form of CD21 (soluble CD21, or sCD21) in their blood than healthy 
controls(285).  The significance of these observations is unknown. 
Why an intact complement system has a protective effect for SLE when the pathology 
of the disease results largely from complement activation has been the subject of much study 
and debate.  Currently, two hypotheses are prominent: the clearance hypothesis and the 
tolerance hypothesis(35).  The clearance hypothesis states that because the complement 
system is needed for effective clearance of apoptotic cells(286, 287), a deficiency in 
complement increases the apoptotic cell burden, and therefore available antigen, which 
activates autoreactive B cells.  However, C3 is important in apoptotic cell clearance, and 
deficiencies in C3 do not predispose to SLE(279, 288-290).  The tolerance hypothesis states 
that because complement plays an important role in B cell selection and regulation, as well as 
antigen processing and presentation, complement deficiency allows escape of autoreactive B 
cells from central and/or peripheral regulation. 
It is still unclear why certain environmental exposures can act to induce or exacerbate 
lupus. It is likely that many mechanisms are involved; however, one property that all these 
exposures share is their ability to induce apoptosis, either directly or through the formation of 
reactive oxygen species(291-293). This has led to the hypothesis that these exposures induce 
ANAs by increasing exposure of autoreactive B cells to apoptotic cells, which display self 
antigen(294). Supporting this idea, direct intravenous (IV) injection of apoptotic cells into 
mice results in production of ANA(260, 295). 
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There have been many other abnormalities found in SLE patients.  Overall decrease 
in CD19 expression has been shown in patients with SLE(296, 297), but subsets of B cells 
overexpress CD19 in these patients and in patients with common variable immunodeficiency 
(CVID) with autoimmune phenomena(283, 298).  Increases in CD19 expression of as little as 
20% can break tolerance in mice, and overexpression of CD19 has been shown in patients 
with the autoimmune disease systemic sclerosis(297, 299), supporting a role for CD19 
dysregulation in autoimmunity. 
PB B cells from SLE patients are also hyperactive and show spontaneous Ig 
production, reduced susceptibility to Ag-induced cell death, elevated Ca2+ responses, and 
hyperphosphorylation of cytosolic proteins(300-304).   In addition, SLE Pts have increased 
numbers of activated, memory, and B-1 B cells in their PB(305-309).  Interestingly, recent 
data implicate dysregulation of the inhibitory receptor FcR2b on B cells, particularly 
memory B cells, as a possible causative factor in SLE(266, 310).  The importance of these 
findings is still not well understood. 
3. Clinical Aspects of SLE 
 
The American Collage of Rheumatology requires the presence of at least 4 of 11 
specific criteria for the diagnosis of SLE.  The criteria can be found in Table 1.5(311).  
Among the most clinically devastating and life-threatening consequences of SLE is renal 
disease; almost all patients, if left untreated, will develop end-stage renal disease (ESRD) and 
die from this complication.  Another life-threatening consequence of SLE is the  
dysregulation of clotting, leading to transient ischemic attacks (TIAs), strokes, and 
myocardial infarctions.  In addition, SLE Pts often experience a paradoxical 
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immunodeficiency marked by leukopenia.  As can be seen in table 1.5, essentially all systems 
of the body can be adversely affected by this disease. 
 
Table 1.5. Diagnostic criteria for SLE. 
Malar rash Fixed erythema, flat or raised, over the face 
Discoid rash Erythematous circular raised patches with adherent keratotic scaling and follicular plugging 
Photosensitivity Exposure to UV light causes rash 
Oral ulcers Oral and nasopharyngeal ulcers 
Arthritis Nonerosive arthritis of two ore more peripheral joints, with tenderness, swelling or effusion 
Serositis Pleuritis or pericarditis 
Renal disorder Proteinuria or cellular casts 
Neurologic disorder Seizures or psychosis without other causes 
Hematologic disorder Hemolytic anemia, leukopenia, lymphopenia, or thrombocytopenia 
Immunologic disorder Anti-dsDNA, anti-Sm and/or anti-phospholipid 
Antinuclear antibodies An abnormally elevated ANA titer 
4. Treatment of SLE 
 
For many years, the treatment of SLE has been general immune suppression, since 
there is no cure for the disease.  Drugs used depend largely on severity of disease, presence 
or absence of acute flare, and systems involved.  Non-life threatening disease can be 
managed with mild pharmaceuticals such as non-steroidal anti-inflammatory drugs 
(NSAIDs).  Antimalarials, such as chloroquine, also have efficacy in treatment of both 
symptoms and flares of SLE.  They are presumed to exert their effects via blocking 
acidification of endosomes preventing both MHCII presentation and TLR signaling.  More 
severe disease must be controlled with systemic glucocorticoids such as prednisone, or with 
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other potent immunosuppresents, which in many cases double as chemotherapeutic agents, 
such as azathioprine and cyclophosphamide.  This is unfortunate given the frequent and 
severe adverse effects associated with these drugs(249). 
 Given the substandard efficacy and significant side effect profiles of these therapies, 
new treatments for SLE are constantly under investigation.  The newest is rituximab (trade 
name, Rituxan), which was developed for use in B cell leukemias and lymphomas, 
particularly non-Hodgkin’s lymphoma(312-314).  Because its mechanism of action is 
depletion of B cells, rituximab has been evaluated for treatment of SLE, RA, multiple 
sclerosis, and other autoimmune diseases(312, 315-317).  Rituximab is a monoclonal 
antibody which recognizes the B cell specific marker CD20.  The precise mechanisms by 
which it accomplishes B cell depletion are unclear and are under active investigation, 
although it appears that this process is mediated, at least in large part, by Fc receptors(318-
320). 
Studies evaluating the efficacy of Rituximab in SLE have determined that response is 
variable: about a third respond with a extended clinical remission from the disease, a third 
respond to the drug short-term (less than 12 months), and a third do not respond at all(315, 
321) (and Anolik and Sanz, unpublished data).  Interestingly, in mouse models of Rituximab 
therapy, autoimmune strains were more resistant to depletion than non-autoimmune 
strains(322) (and Shlomchik et al, unpublished data). Therefore, Rituximab may emerge as a 
new therapy for a subset of SLE Pts, but new drugs with increased efficacy and fewer severe 
side effects are desperately needed(249, 323). 
B. ANCA-Associated Small Vessel Vasculitis (ANCA-SVV) 
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Anti-neutrophil cytoplasmic antibodies (ANCA) recognize proteins in the granules of 
neutrophils and monocytes.  They are present in a number of autoimmune diseases, and 
multiple subtypes of ANCA have been identified(249).  Within the scope of this work, only 
ANCA-associated small vessel vasculitis (ANCA-SVV) will be discussed. 
 ANCA-SVV is mediated by autoantibodies directed against myeloperoxidase (MPO-
ANCA)(324) or proteinase 3 (PR3-ANCA)(325, 326).  Besides pathogenesis mediated by 
autoantibody, it shares with SLE the propensity to develop pauci-immune necrotizing 
glomerulonephritis, leading to rapid loss of kidney function.  Other similarities to SLE 
include relapsing and remitting course, similar pharmaceutical treatment regimens(327, 328), 
and manifestations in multiple organ systems(329). Additionally, in both diseases, the 
severity and rate of progression can vary from an insidious course to that of fulminant, life-
threatening, multiorgan disease(311, 330), and in both, at least a subset of patients can be 
successfully treated with Rituximab(323).  
III. SUMMARY OF DISSERTATION 
 
The data presented herein implicate CD19 dysregulation in the pathogenesis of SLE 
and ANCA-SVV.  We show decreased CD19 expression on PB B cells in >95% of patients 
with either disease, and hypothesize that this decrease may allow escape of autoreactive 
specificities from regulation by decreasing the strength of signal generated by the interaction 
of the BCR and autoantigen.   
Additionally, we show that CD19 expression is 2-3 fold increased on a subset of 
memory cells in 25-30% of SLE and ANCA-SVV patients.  These CD19hi cells have many 
features of conventional memory B cells, but also appear to represent a novel and distinct 
subset of activated memory B cells which is enriched for autoreactive specificities.  Our data 
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suggest that these cells travel to sites of inflammation, proliferate, and differentiate to PC; 
they also appear to be precursors to at least a portion of the autoantibody in circulation. 
Finally, we show that patients with an expanded CD19hi population (CD19hi patients) 
experience an increased frequency of adverse outcomes, a unique pattern of autoreactive 
antibody specificities, and poor or non-responsiveness to rituximab therapy.  Taken together, 
these data suggest that CD19hi patients represent a distinct subset of SLE with particular 
clinical features and therapeutic requirements. 
 
CHAPTER 2: SIMILAR CD19 DYSREGULATION IN TWO 
AUTOANTIBODY-ASSOCIATED AUTOIMMUNE DISEASES 
SUGGESTING A SHARED MECHANISM OF B CELL 
TOLERANCE LOSS 
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I. ABSTRACT 
 
We report here that dysregulation of CD19, a co-receptor that augments B cell receptor 
(BCR) signaling, occurs at two B cell differentiative stages in patients with systemic lupus 
erythematosus (SLE) and anti-neutrophil cytoplasmic antibody (ANCA) associated small 
vessel vasculitis (SVV).  The naïve B cells of nearly all SLE and ANCA-SVV patients 
express ~20% less CD19 than healthy control (HC) B cells.  In contrast, a subset of memory 
B cells of some SLE and ANCA-SVV Pts (25-35%) express 2-4 fold more CD19 than HC B 
cells.  These CD19hi memory B cells are activated and exhibit evidence of antigen selection.  
Proteome array analysis of 67 autoantigens indicates that CD19hi SLE Pts exhibit a distinct 
autoantibody profile characterized by high levels of antibodies to small nuclear 
ribonucleoproteins and low levels of anti-glomerular autoantibodies.  These findings have 
implications for autoreactive B cell activation and suggest a shared mechanism of B cell 
tolerance loss in these two diseases. 
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II. INTRODUCTION 
 
The two most common forms of aggressive glomerulonephritis leading to the rapid 
loss of kidney function are glomerular immune complex deposition in systemic lupus 
erythematosus (SLE) and pauci-immune necrotizing glomerular diseases mediated by anti-
neutrophil cytoplasmic autoantibodies (ANCA).  Clinically, SLE and ANCA are rarely 
associated, but they do have some commonalities.  Both diseases are tightly associated with 
well-characterized autoantibodies against intracellular proteins;  SLE with autoantibodies 
directed against nuclear proteins, histones, and DNA(331, 332), and ANCA associated small 
vessel vasculitis (ANCA-SVV) with autoantibodies directed against myeloperoxidase (MPO-
ANCA)(324) or proteinase 3 (PR3-ANCA)(325, 326).  Moreover, both are marked by a 
relapsing and remitting clinical course, are treated with similar immunosuppressive 
regimens(327, 328), and can present with protean manifestations of inflammation involving 
organs such as the lungs, upper airways, skin, joints, and central and peripheral nervous 
systems(329).  The acuity and rate of disease progression varies from an insidious course to 
that of fulminant, life-threatening, multiorgan disease(311, 330).  
Previous studies of peripheral blood (PB) B cells in human SLE have revealed 
differences from normal B cells.  In comparison to healthy control (HC) B cells, PB B cells 
in human SLE patients (Pts) are hyperactive(300).  Moreover, they show spontaneous Ig 
production, reduced susceptibility to Ag-induced cell death, elevated Ca2+ responses, and 
hyper-phosphorylation of cytosolic proteins(300-304).  SLE Pts are also reported to have a 
higher number of activated (CD86+), memory (CD27+), and B-1 (CD5+) PB B cells(305-
309).  In contrast, almost nothing is known about B cells in ANCA-SVV.   
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Imbalances in the positive and negative influences on B cell receptor (BCR) signal 
strength may contribute to human autoimmunity(152).  Alteration in CD19 expression has 
emerged as a possible mechanism for creating an imbalance in BCR signaling that leads to 
autoimmunity.  CD19 complexes with CD81, Leu13, and CD21, the receptor for complement 
component C3d(g)(132, 333), and is a BCR co-receptor that enhances BCR signal 
transduction.  CD19 functions as the signaling component for CD21(132), although it can 
also function independently of CD21(132, 146). Complexes of antigen and C3d(g) are at 
least 1000 times more potent in B cell activation than antigen alone(1).  CD19 density on B 
cells of systemic sclerosis Pts is ~20% higher compared to B cells from HCs(297).  In 
contrast, SLE PB B cells appear to express low levels of CD19(296, 297).  A population of 
PB CD19hi B cells has been described in Pts with common variable immunodeficiency 
(CVID) with autoimmune phenomena, as well as in SLE Pts(283, 298).  Thus, CD19 
dysregulation may link several autoimmune diseases.  
We report here a similar aberrant CD19 regulation in SLE and ANCA-SVV.  In both 
diseases, naïve B cells express ~20% less CD19 than HC B cells.  Some Pts also have a 
subset of memory B cells that expresses 2 to 4 fold more CD19 than naïve or memory HC B 
cells.  The CD19hi B cells have an activated phenotype and show evidence of antigen 
selection.  In SLE, the presence of CD19hi B cells is associated with anti-ribonucleoprotein 
(RNP) production and neurological dysfunction.  These findings suggest that aberrant CD19 
expression occurs at the naïve and memory stages of B cell development in human SLE and 
ANCA-SVV, and may contribute to disease onset and relapse. 
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III. MATERIALS AND METHODS 
 
Pt and HC samples 
 
PB samples were collected from 10 HCs and 41 SLE Pts (Table 2.1) (HC: 30 years, 
range: 25-30, gender: 4 female, 4 male; SLE: 37 years, range: 20-83, gender: 35 female, 4 
male).  SLE Pts were included in this study after informed consent in accordance with our 
institutional internal review board, and fulfilled at least 4 of the established American 
College of Rheumatology 1997 revised criteria for SLE.  Clinical and serological data were 
gathered during routine clinic visits at the time of blood draw for B cell analysis.  The SLE 
disease activity score (SLEDAI)(334) and British Isles Lupus Assessment Group (BILAG) 
index(335) scores were calculated for each Pt to reflect disease activity at the time of the 
sample collection. 
PB samples were collected from 6 healthy donors (different from those used for the 
SLE Pt analysis) and 24 ANCA-SVV Pts (Table 2.2) after informed consent.  Patients were 
classified as having active or inactive disease based on their Birmingham Vasculitis Activity 
Score (BVAS); any patient with a BVAS >1 was considered active.  Healthy controls (HC) 
averaged 36.5 years and ANCA-SVV Pts averaged 47.6 (MPO-ANCA-SVV) and 53.7 years 
(PR3-ANCA-SVV).   
HCs used for the comparison of CD19 levels on naïve and memory B cells included 7 
females and 2 males, and averaged 30.5 years of age. The analysis of these samples was done 
at the same time and used a population of HCs distinct from those used for comparison with 
Pt B cells.   
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Renal disease was determined by renal biopsy.  The Nephropathology Laboratory at 
the University of North Carolina performed the analysis and the results were classified by 
standard criteria as described(336).  
 
Cell preparation and cell surface staining 
 
PB mononuclear cells (PBMCs) were purified from heparinized PB samples (~20 ml) 
by Ficoll centrifugation.  The buffy coat was washed twice in PBS and resuspended in RPMI, 
2% fetal calf serum (FCS), 0.1% sodium azide for cell surface staining.  Cells were stained 
with previously determined optimal concentrations of the following fluorochrome labeled 
antibodies: anti-human CD19-APC, IgD-FITC, IgG-FITC, CD38-PE, CD86-PE, CD40 PE, 
and MHCII-FITC (Pharmingen, San Diego, California) and then fixed with 1% 
paraformaldehyde.   
 
Anti-Sm ELISA 
 
The anti-Sm ELISA was performed as previously described(337) except that the 
secondary antibodies were a goat anti-human IgG (H+L) horseradish peroxidase (Jackson 
Immunoresearch, Westgrove, Pennsylvania) at a 1:10,000 dilution.  Positive anti-Sm control 
serum (Immunovision, Springdale, Arizona) was used to normalize plate-to-plate variation.  
A positive well was defined as three times background (secondary alone) and the titer was 
calculated as the inversion of the most dilute sample giving a positive result. 
 
Molecular analysis of VH region from PB B cells 
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PB B cells from an SLE Pt with an expanded CD19hi population were stained for 
CD19 expression and individual CD19hi B cells were sorted into a 96 well plates that had 
been covalently coated with oligo-dT (RNAture, Irvine, California) for sequence analysis as 
described previously by Arnold and McCray(338). Oligonucleotide mixtures were used as 
reported previously, although modified by removal of the restriction sites(339) (VHL-1: 5’-
TCACCATGGACTGSACCTGGA-3’, VHL-2: 5’-CCATGGACACACTTTGYTCCAC-3’, 
VHL-3: 5’-TCACCATGGAGTTTGGGCTGAGC, VHL-4: 5’-
AGAACATGAAACAYCTGTGGTTCTT-3’, VHL-5: 5’-ATGGGGTCAACCGCCATCCT-
3’, VHL-6: 5’-ACAATGTCTGTCTCCTTCCTCAT-3’, CuII: 5’-
CAGGAGACGAGGGGGAAAAG-3’, CyII:5’-GCCAGGGGGAAGACSGATG-3’).  A 
second nested PCR was done using products from the first PCR with the following primers 
(VH-1: 5’-CAGGTSCAGCTGGTRCAGTC-3’, VH-2: 5’-
CAGRTCACCTTGAAGGAGTCTG-3’, VH-3: 5’-SAGGTGCAGCTGGTGGAGTC-3’, 
VH-4: 5’-CAGGTGCAGCTGCAGGAGTC-3’, VH-5: 5’-GARGTGCAGCTGGTGCAGTC-
3’, VH-6: 5’-CAGGTACAGCTGCAGCAGTCA-3’, CuIII: 5’-
GAAAAGGGTTGGGGCGGATGC-3’, CyIII: 5’-ACSGATGGGCCCTTGGTGGA-3’).  
The products of the second PCR were analyzed on a 1.2% agarose gel; PCR products were 
cleaned and concentrated by Qiagen PCR Purification Kit (Qiagen, Chatsworth, California).  
DNA was sequenced using the second PCR 3’ primer by the Automated DNA Sequencing 
Facility at UNC.  VH genes were identified using Ig BLAST 
(http://www.ncbi.nlm.nih.gov/igblast/).     
 
Analysis of mutations 
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The action of selection on mutated Ig genes was assessed by analyzing the sequences 
with the program SoDA(340), which finds the best putative pre-mutation rearrangement and 
identifies mutations.  All mutations falling into framework regions (FWR) and 
complementarity determining regions (CDRs) were separately classified by codon position 
(1, 2 or 3).  In the absence of selection, mutations will be distributed uniformly over codon 
positions; in the presence of selection, more mutations at codon positions 1 and 2 will be 
purged than mutations at codon position 3, resulting in an apparent excess of mutations at 
position 3.  Furthermore, selection differential between positions 1 and 2 may occur, 
depending on the relative conservation of the amino acid changes resulting on average in 
nucleotide changes in the two positions.  Departure from the uniform distribution over codon 
positions was assessed by a chi-squared goodness of fit test. 
 
Proteome array analysis 
 
The proteome array analysis was performed as previously described(341) using 
HydroGel coated slides spotted with a panel of glomerular and nuclear antigens.  The spotted 
antigens included aggencan, -actinine, amyloid, 2-glycoprotein, 2-microglobulin, C1q, 
cardiolipin, CENP-A, CENP-B, chondroitin, chromatin, collagen I, collagen II, collagen III, 
collagen IV, ssRNA, cytochrome C, cytochrome P45, DSPG, dsDNA, elastin, fibrinogen IV, 
fibrinogen S, fibronectin, gliadin, glomerular basement membrane, glomerular sonicate, good 
pasteur antigen, histone (H) 1, H2A, H2B, H3, H4, hen egg lysozyme, hemocyanin, heparan 
sulfphate proleoglycan, heperin, hyaluronic acid, intrinsic factor, JO-1, Ku (p70/p80), La/SS-
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B, laminin, matrigel, myosin, PL-12, PL-7, PM/Scl-100, proliferating cell nuclear antigen, 
proteoglycan, ribosomal phosphoprotein PO, Ro/SS-A (52KDa), Ro/SS-A(60KDa), Scl-70, 
ssDNA, thyroglobulin, topoisomerase, total histone, TPO, TTG, U1-snRNP-68, U1-snRNP-
A, U1-snRNP-BB’, U1-snRNP-C, vimentin, vitronectin, and yeast tRNA.  The data were 
analyzed also as previously described(341). IgG and IgM serum levels were determined 
using human IgM and pan IgG ELISA kits (Bethyl Laboratories, Montgomery, TX). 
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IV. RESULTS 
 
The majority of SLE and ANCA-SVV PB B cells were CD19lo.
PBMCs were isolated from 41 SLE and 24 ANCA-SVV Pts, stained with B cell 
specific antibodies, and analyzed by flow cytometry.  ANCA-SVV Pts were selected at 
random.  SLE Pts were initially selected for the presence of elevated anti-Sm titers; hence 
there was a 50% prevalence of patients with an anti-Sm titer, rather than the expected 
30%(342).  A HC was stained with each experiment to control for day-to-day variation in cell 
surface staining.   
The majority of SLE and ANCA-SVV B cells resembled HC B cells in that they 
comprised a single B cell population of uniform CD19 staining intensity and size (Fig. 2.1A).  
However, as reported previously(296, 297), SLE B cells expressed low levels of CD19.  
Surprisingly, the majority of B cells from ANCA-SVV Pts were also CD19lo. Due to the 
high degree of variability of the CD19 median fluorescence index (MFI) on B cells stained 
on different days, comparisons were made only between a Pt and HC stained on the same 
day.  As shown in Fig. 2.1B and C, SLE and ANCA-SVV Pt B cells stained ~18% (range: 3-
45%) and ~20% (range: 15-67%) less well for CD19 than HC B cells, respectively (Fig. 
2.1C) (P<0.01; Wilcoxon’s signed-ranks test).  This is unlikely to be due to treatment since B 
cells of untreated ANCA-SVV Pts were also CD19lo (P<0.01; Wilcoxon’s signed-ranks test) 
(Fig. 2.1C).  The majority (>90%) of CD19lo B cells were IgD+, CD38+, and CD27- (Fig. 
2.1D and data not shown) and thus appeared to be naïve B cells.   
 
CD19hi PB B cells were present in a subset of SLE and ANCA-SVV Pts. 
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Our analysis also revealed a CD19hi B cell population in a subset of SLE and ANCA-
SVV Pts (Fig. 2.1A).  This differs from a previous report of the presence of CD19hi B cells in 
all SLE Pts (283).  Based on a criterion of more than 2 standard deviations above the mean 
percentage of CD19hi HC B cells, a CD19hi B cell population was detected in 14 of 41 
(34.1%) SLE Pts and 6 of 24 (25%) ANCA-SVV Pts, but none of the HCs (Fig. 2.2A, B).  
Among the 14 SLE CD19hi Pts, ~7.5% PB B cells were CD19hi in contrast to 3.5% in the 
remaining SLE Pts and 2.5% in HCs.  Similarly, among the 6 CD19hi ANCA-SVV Pts, ~11% 
of PB B cells were CD19hi, in contrast to ~4% among the remaining 18 Pts.  SLE and 
ANCA-SVV CD19hi B cells stained an average of 216% (range: 137-302%) and 369% 
(range: 274-422%) brighter, respectively, for CD19 than the CD19lo B cells of the same Pt 
(Fig. 2.2C) (P<0.01; Wilcoxon’s signed-ranks test) (Fig. 2.2C).  Four SLE pts were analyzed 
2 or more times over a period of two years and, although fluctuation in frequency occurred, a 
CD19hi population was detected each time (Fig. 2.2D and data not shown).  In addition, two 
ANCA-SVV Pts lacked a CD19hi B cell population on initial analysis, but developed a 
CD19hi population by the time of a second analysis (Fig. 2.2D and data not shown, Table 2).  
Thus, once it appears, the CD19hi population seems to be relatively stable over time.  Herein, 
Pts with a CD19hi population will be referred to as CD19hi Pts, and those without a CD19hi 
population will be referred to as CD19lo Pts.    
 
CD19hi B cells are memory B cells 
 
To determine the differentiative stage of CD19hi B cells, we determined their BCR 
isotype and Bm classification. Approximately 43% of the CD19hi B cells of SLE Pts were 
IgG+, as opposed to ~7% and ~5% of PB B cells from HCs and SLE Pts that lack a CD19hi B 
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cell population (Fig. 2.3A) (P=0.0001 and 0.0001, respectively; Student’s t test).  
Conversely, ~37% of CD19hi B cells were IgD+, versus 83% and 91% of PB B cells in HCs 
and SLE Pts that lacked a CD19hi B cell population (Fig. 2.3A) (P=1.14 x 10-5 and 2.90 x 10-
5, respectively; Student’s t test). The CD19lo B cells in Pts with a CD19hi B cell population 
resembled HC B cells in both IgG and IgD expression (Fig. 2.3A).  Similarly, the percent 
IgD+ B cells among CD19hi B cells of ANCA-SVV Pts and HCs was significantly different 
(56% vs.75%, respectively; P<0.5; Student’s t test) (Fig. 2.3A), although the percent IgG+ B
cells did not reach the level of significance (22% vs. 10%, respectively) owing to the small 
sample size (n=6) and considerable variability among Pts.  Thus, the CD19hi B cell 
population is enriched in IgG+ B cells. 
CD38 and IgD staining was used to further assess CD19hi B cell identity(198).  Most 
SLE and ANCA-SVV CD19hi B cells were IgD- CD38-/low memory B cells (Bm5), with a 
minority of IgD+, CD38- B cells (Bm1).  The Bm1 subset includes both IgD+ memory and 
naïve B cells (Fig. 2.3B and C). CD27 expression was variable among CD19hi B cells (data 
not shown). CD27 has been used as a memory B cell marker, but recent evidence indicates 
that some PB memory B cells are CD27-(199), which appears to be the case here.  In 
contrast, the CD19lo B cells of SLE and ANCA-SVV Pts were primarily activated naïve B 
cells (CD38+ IgD+ Bm2), but also included memory B cells (Fig. 2.3B and C).  The few B 
cells that fall within the CD19hi B cell gate in HCs and Pts lacking a CD19hi B cell 
population were IgD+, CD38+ activated naïve B cells (Bm2) (data not shown).  Thus, in 
keeping with their BCR isotype, the majority of CD19hi B cells had a memory B cell 
phenotype, while a minority had a Bm1 phenotype and accordingly could be either naïve B 
cells or unswitched memory B cells. 
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CD19hi B cells are polyclonal, somatically mutated, and antigen selected. 
 
To assess clonality and selection within the CD19hi B cell population, we determined 
the sequences of the expressed VH region genes from 39 randomly selected CD19hi B cells 
(20 IgM, 19 IgG) from an SLE Pt.  Each sequence had a unique VDJ gene rearrangement and 
thus was of independent clonal origin (data not shown).  VH gene use by CD19hi B cells 
exhibited a bias for VH1 family genes (Fig. 2.4A), which included multiple members (data 
not shown), suggestive of antigen selection.  This contrasts with previous reports of a bias for 
VH3 (~50%) by both SLE and HC B cells(343, 344).  This VH1 bias by CD19hi B cells was 
due to the IgG+ B cells, as almost half of the  sequences were VH1, in contrast to just 20% of 
µ sequences.  There was no apparent bias in complementarity determining region 3 (CDR3) 
length (median length: 39 bps for both µ and  sequences) or JH use among CD19hi B cells 
(data not shown).  Comparison to germline sequences identified by Ig BLAST indicates that 
the expressed VH genes from the IgG+ CD19hi B cells were heavily mutated (Fig. 2.4B) 
(median:14 mutations/VH), consistent with a memory B cell identity.  In contrast, the VH
genes from the IgM+ cells exhibited few mutations (median: 1 mutation/VH) (Fig. 2.4B).   
There was a significant bias in the distribution of H chain somatic mutations in 
CD19hi B cells.  Mutations were classified by codon position (1, 2, or 3) and analyzed for 
departure from a uniform distribution using a 2goodness of fit test.  The 231 mutations in 
the framework encoding regions fell more frequently into the third position of the codons 
than would be expected by chance alone (expected distribution is 77 at each position; actual 
distribution is 73, 59 and 99 at codon positions 1, 2, and 3, respectively; 2 = 10.7, p = 
2.4×10-3).  This distribution suggests selection against amino acid replacement mutations in 
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FWRs.  In contrast, the 135 mutations in CDR 1 and 2 encoding regions occurred more 
frequently in codon position 2 and less frequently in position 1 than expected by chance 
(expected distribution is 45 at each position; actual distribution is 32, 56, and 47 mutations in 
codon positions 1, 2, and 3, respectively; 2 = 6.53, p = 0.019; the CDR3 encoding region 
was excluded because of the inability to distinguish N region nucleotides and somatic 
mutation).  This suggests a bias for amino acid replacement mutations in CDRs, consistent 
with antigen selection of mutant CD19hi B cells.   
 Antigen selection of CD19hi B cells was further suggested by the presence of shared 
mutations, particularly in CDR2 and FW3 (Fig. 2.4C).  For example, S51I and M87T 
occurred in all three B cells expressing VH1-3, and 6 other replacement mutations (M34I, 
G53A, E62K, S76T, A78V, and S82aN) occurred in two of the three cells.  Altogether, there 
were 19 instances of the identical mutation occurring in 2 or more cells expressing the same 
VH gene (Fig. 2.4C).  Interestingly, 17 of these mutations occurred in VH1 family genes (Fig. 
2.4C) reinforcing the idea of selection for VH1 gene use by CD19hi B cells.  
 
CD19hi B cells have an activated phenotype. 
 
To determine whether CD19hi B cells were activated, we examined the expression of 
activation markers.  Indicative of an activated phenotype, SLE and ANCA-SVV CD19hi B 
cells expressed higher levels of CD86 and MHCII than CD19lo B cells from the same Pt and 
HC B cells analyzed on the same day (Fig. 2.5).  Their larger size and increased granularity 
(Fig. 2.1 and data not shown) was also suggestive of activation, as was low expression levels 
of CD21 (Fig. 2.5)(284).  In contrast, the expression of the activation marker CD40 was 
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lower on CD19hi B cells than on HC B cells or CD19lo B cells.  Overall, these data suggest 
that CD19hi B cells are activated.   
 
An increase in CD19 expression accompanies differentiation to a memory B cell.  
 
As CD19hi B cells were predominantly memory B cells, we determined whether 
differentiation to a memory B cell results in increased CD19 expression.  Naïve and memory 
B cells from 10 HCs were compared in a single experiment, and in all cases memory B cells 
(IgD-, CD38-/lo) stained ~30% (range: 11-53%) brighter for CD19 than naïve B cells (IgD+,
CD38+) from the same individual (P=3x10-5; Student’s t test) (Fig. 2.6A and B).  Notably, 
SLE and ANCA-SVV Pts with a CD19hi B cell population also had a population of memory 
B cells with levels of CD19 similar to those of HCs (Fig. 2.6A).  Thus, differentiation to a 
memory B cell normally results in increased CD19 expression, but cannot fully explain the 
levels seen on CD19hi B cells. 
 
Correlation of the presence of a CD19hi B cell population with clinical features of disease. 
 
To determine whether the presence of a CD19hi B cell population was associated with 
more active disease or specific disease manifestations, we tested for correlations with clinical 
findings recorded for each Pt on the day of sample collection.  No correlation with the 
SLEDAI or BILAG scores was observed in SLE, nor was a correlation observed with 
ANCA-SVV disease severity, as measured by BVAS scores (Tables 2.1 and 2.2).  There was 
no correlation of the presence of a CD19hi B cell population with renal disease, as determined 
by biopsy, or with creatinine levels or proteinuria (data not shown).  Thus, CD19hi B cells are 
present in Pts with active and inactive disease and are not an indicator of disease activity.   
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However, the presence of a CD19hi population among SLE Pts correlated 
significantly (P=0.01) with neurologic dysfunction (seizure or psychoses).  A CD19hi 
population also correlated with a high anti-Sm titer (Table 2.1); 8 of 14 CD19hi Pts (mean 
titer of 400), but only 13 of the 29 non-CD19hi Pts (mean titer of zero) had an elevated anti-
Sm titer (P= 0.01; Student’s t test) (Fig. 2.7A).  No association was found with the presence 
of anti-nuclear antibodies (ANAs).  In addition, both anti-MPO and anti-PR3 were observed 
among CD19hi ANCA-SVV Pts (Table 2.2) indicating no association with either 
autoantibody.  
To determine whether there were other differences in autoantibody specificities 
associated with CD19hi SLE Pts, we screened Pt serum using autoantigen proteome arrays 
bearing 67 nuclear and glomerular autoantigens(341).  SLE Pts exhibited basal or negligible 
reactivity to most of these autoantigens with several important exceptions. Among these, the 
IgG autoantibody specificities uncovered fell into several distinct reactivity groups. 1) Three 
autoantibody specificities, Ro/SSA (52kD), CENP-A, and CENP-B were significantly 
elevated among the SLE patients, particularly those who lacked CD19hi B cells (Fig. 2.7B 
and data not shown). Whereas most of CD19lo patients exhibited significantly elevated titers 
of anti-Ro/SSA autoantibodies, only a small subset of the CD19hi patients exhibited elevated 
levels of these autoantibodies (Fig. 2.7B). Indeed, these were amongst the highest level of 
autoantibody specificities the SLE patients exhibited. 2) IgG autoantibodies to chromatin, 
dsDNA, PCNA, La/SSB, glomerular sonicates, and the core histones, H2A, H2B, H3 and 
H4, were equally elevated in CD19lo and CD19hi patients (Fig. 2.7B and data not shown).  3) 
SLE patients had reduced IgG autoantibody levels to fibrinogen, heparin sulphate, heparin, 
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laminin, and matrigel, compared to the healthy controls (Fig. 2.7B), and these reactivities 
were even lower among CD19hi patients.  4) Finally, it was remarkable that a small subset of 
autoantigens were selectively targeted by the sera from CD19hi SLE patients, including 
ribosomal phosphoprotein PO, U1snRNP-68, U1snRNP-A and U1snRNP-B/B’ (Fig. 2.7B). 
Indeed, these appeared to be the hallmark specificities of CD19hi sera since the titers of these 
autoantibodies far exceeded the levels of all other specificities assayed in these sera and 
several of these autoantibodies were also significantly higher than the corresponding levels in 
CD19lo SLE patients. Notably, almost all CD19hi sera exhibited elevated levels of IgG 
autoantibodies to U1snRNP-A and U1snRNP-B/B’ compared to the HCs (Fig. 2.7B).  
IgM antibodies were assayed using the same autoantigen proteome arrays. 
Surprisingly, all autoantibody specificities exhibited a fairly similar pattern, with the levels 
being lower in the SLE sera compared to basal levels in the HCs (Fig. 2.7C). Interestingly, in 
the case of some of these specificities, including La/SSB, cardiolipin, H2B, and ribosomal 
phosphoprotein PO, the IgM autoantibody levels were even more depressed in CD19hi Pt 
sera.  Since the IgM and IgG specificities were assayed using the same arrays, the IgG:IgM 
ratios for the different specificities were readily ascertained. Because all IgM specificities 
were depressed in the SLE sera, all autoantibodies that were uncovered in the SLE sera were 
heavily skewed towards the IgG isotype (data not plotted). 
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V. DISCUSSION 
 
Our findings indicate a striking similarity in CD19 dysregulation by the B-cell-
mediated autoimmune diseases SLE and ANCA-SVV.  Low CD19 expression by naïve B 
cells occurs with near complete penetrance in both diseases, while high CD19 expression by 
a subset of memory B cells occurs with a 25-35% penetrance in both diseases.  Thus, 
although the autoantibodies produced in SLE and ANCA-SVV mediate disease by different 
mechanisms—immune complex deposition and premature induction of neutrophil 
degranulation on vessel walls, respectively(345, 346)—SLE and ANCA-SVV Pts exhibit 
strikingly similar CD19 dysregulation. This suggests that diseases which are marked by 
production of autoantibodies, regardless of their specificity, may share a common mechanism 
of B cell tolerance loss. 
 
CD19lo naïve B cells in SLE and ANCA-SVV 
 
Naïve SLE and ANCA-SVV B cells stain ~20% less well for CD19 than HC B cells, 
as previously observed in SLE(296, 297), suggestive of low CD19 expression.  Treatment is 
unlikely to be responsible, since naïve B cells of untreated ANCA-SVV Pts are also CD19lo 
(Fig. 2.1C).  Low CD19 levels can decrease sensitivity to activation through the BCR and 
thus could contribute to the immunodeficiency experienced by SLE Pts(347), and could 
affect differentiation to the follicular, marginal zone, or B-1 cell subsets, as has been shown 
in mice(47).  More importantly, autoreactive CD19lo B cells may escape tolerance induction, 
since it is dependent upon BCR signal strength.  This could explain the higher frequency of 
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autoreactive B cells observed among immature and naïve B cell populations in human 
SLE(348).  Congruent with the idea that low CD19 expression contributes to autoimmunity, 
CD19 maps to a region of chromosome 16 that is linked to SLE(349), and a CD19 
polymorphism associated with SLE in Japanese Pts leads to decreased CD19 mRNA stability 
and low CD19 expression levels(350).  In addition, a single nucleotide polymorphism 
upstream of the human CD19 gene is associated with high CD19 expression levels in 
systemic sclerosis(351).  
 
CD19hi memory B cells in SLE and ANCA-SVV. 
 
A subset of SLE and ANCA-SVV Pts (34.1% and 25%, respectively) has a CD19hi 
memory B cell population.  The prevalence in SLE is likely to be somewhat lower, since SLE 
Pts were initially selected for having high serum anti-Sm titers, and we observe an 
association of CD19hi B cells with high circulating anti-Sm titers and other snRNP antigens 
(Fig. 2.7A).  Among CD19hi SLE and ANCA-SVV Pts, CD19hi B cells constitute a 
substantial fraction of PB B cells (approximately 7.5% and 11%, respectively) (Fig. 2.1A and 
B). Although fluctuation in frequency occurs within Pts over time, and some ANCA-SVV 
Pts were observed to gain a CD19hi population, once it appears this population is relatively 
stable, as it is present during active and inactive disease and remains a significant population 
over time (Tables 2.1 and 2.2, and Fig. 2.2D).  Most CD19hi B cells are IgG+ Bm5 memory B 
cells (Fig. 2.3) and, in at least one SLE Pt, are somatically mutated (Fig. 2.4B), suggesting 
that these cells have passed through a GC.   
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Consistent with a GC origin, the IgG+ CD19hi B cells appear to be antigen selected.  
First, they exhibit a bias in VH1 family gene expression (Fig. 2.4A), in contrast to a VH3 bias 
among IgM+ CD19hi B cells (Fig. 2.4A) and HC B cells(343, 344).  A previous study 
indicated a VH3 bias by SLE B cells(344), but it did not consider individual B cell subsets.  
Analysis of additional Pts is required to determine the generality of this finding and is 
ongoing.  Second, somatic mutation among IgG+ CD19hi B cells is biased in favor of CDR 
amino acid replacement mutations (P=0.019) and against replacement mutations in FWRs 
(P=2.4x10-3), and there are multiple parallel amino acid replacement mutations in VH1
rearrangements (Fig. 2.4C).  The high frequency of VH1 parallel mutation suggests that 
selection is mediated by a limited number of antigens.  We think the selecting antigen(s) are 
likely to be self. In SLE, the selecting antigens may be Sm or other snRNP antigens, since 
very high levels of antibodies to these antigens appear to be the hallmark of CD19hi Pts (Fig. 
2.7B), while in ANCA-SVV the selecting antigens may be MPO and PR3.  This hypothesis is 
currently being tested.  
The activated phenotype of CD19hi B cells (Figs. 2.1 and 2.5) suggests a recent or 
ongoing engagement with antigen, and thus these cells may be undergoing ASC 
differentiation.  The 2-4-fold higher CD19 levels on these cells may confer increased 
sensitivity to activation by antigen, promoting ASC differentiation, as seen in mice with a 
much smaller increase (30%) in CD19 levels(152).  If CD19hi memory B cells are indeed 
more sensitive to activation by antigen and are autoreactive, they likely contribute to disease 
progression and relapse.  A precise determination of their differentiative state, in conjunction 
with identifying the activating antigen(s), will be important to understand their role in 
disease.  Although not associated with increased disease severity as assessed by various 
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clinical scores in either SLE or ANCA-SVV, CD19hi B cells are associated with neurological 
symptoms and anti-RNP antibodies in SLE, suggesting an effect on clinical manifestations of 
disease.  The absence of association with renal disease may be explained by the low levels of 
anti-glomerular antibodies (fibrinogen, laminin, heparin sulfate, Matrigel; Fig. 2.7B), which 
were previously observed to be associated with renal disease(341).  We are currently 
following Pts long-term to determine whether CD19hi B cells are associated with a poorer 
outcome or more frequent relapses.  Overexpression of CD19 by ~20% on systemic sclerosis 
B cells and by B cells in CVID Pts with autoimmune manifestations(297) suggests that 
elevated CD19 is significant to multiple autoimmune diseases. 
Although the molecular basis for CD19 overexpression by memory B cells is 
unknown, our findings provide some insight.  Treatment effects cannot be ruled out; but that 
SLE and ANCA-SVV Pts with and without a CD19hi population receive the same drug 
regimen weakens this explanation.  Genetic factors may be involved, as suggested by the 
possible genetic linkage of CD19 and SLE(349-351).  However, it is noteworthy that 
memory B cell differentiation results in an approximately 30% increase in CD19 expression 
(Fig. 2.6), and that even CD19hi SLE Pts have a memory B cell population with normal 
CD19 upregulation (Fig. 2.6).  Thus, CD19hi B cells appear to represent a unique 
subpopulation of memory B cells in these Pts. This point, along with the finding of skewed 
autoreactivity in CD19hi patients, suggests that CD19 overexpression may be self-antigen 
specific, possibly requiring a combination of antigen and other activating signals, such as 
those through toll-like receptors (TLRs).  A role for TLR signals is an enticing idea, given 
the recent findings strongly implicating dual activation of BCR and TLR receptors in 
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breaking tolerance and generating autoantibodies against nuclear antigens such as dsDNA 
and Sm(8, 9, 11, 352). 
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VI. CONCLUSION 
 
Our data suggest that SLE and ANCA-SVV, although rarely clinically associated, 
share a similar mechanism for loss of B cell tolerance.  We propose that CD19 dysregulation 
affects B cell activation at two stages.  The first is at the CD19lo naïve B cell stage.  It occurs 
with high penetrance in both diseases and may allow autoreactive B cells to evade tolerance 
induction, increasing their likelihood of activation by self.  The second is at the CD19hi 
memory B cell stage.  It occurs with comparatively low penetrance and potentially results in 
increased sensitivity for re-activation.  These findings, along with those of others(283, 298), 
implicate CD19 dysregulation in otherwise distinct antibody-mediated autoimmune diseases 
and point to CD19 as a possible drug target with multiple autoimmune disease applications. 
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Table 2.1. SLE Patients
IDa CD19hi b Medsc Aged Racee Sex Renalf Neurog ANAi -Smj SLEDAIk BILAG
1 + PL,A 41 B F + 6400 2 2
2 + PR 20 AI F + + 400 2 4
10 + PR, C 18 B F + + 200 6 8
12 + PL, PR,C 26 W F + + 400 8 3
14 + PR, CY 20 W F + + + 25600 28 48
16 + PL, C 34 W F + 0 0 03
17 + PL, PR 45 B F 3200 6 5
24 + PL, PR 21 W F + + 0 4 7
23 + PR, A 31 B F + 800 2 2
25 + PL, PR 48 B F + 0 0 2
26 + PR, M 44 B F + 25600 2 2
27 + PR, CY 33 B F + + 25 8 15
36 + PR 25 B F + + 400 4 14
39 + PL, CY 27 B F + 800 28 24
3 PR 40 B F + 0 0 2
6 PL 31 B F + + 800 2 6
5 PL, PR 21 B F + 0 1 3
4 PL, PR 33 B F + 25 0 3
8 PL, PR 50 W F + 0 0 0
7 PL 25 W F + 25 4 1
9 PL, PR, A 28 B F + + 25600 6 6
11 PL, PR 49 B F + + 0 0 8
13 C 32 W F + + 25 2 0
15 C 36 B F + 1600 2 4
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Table 2.1 Cont.
18 none 50 B F + + 25 2 7
19 C 37 B F + 200 2 1
20 PL, C 19 W M + + 0 4 1
21 C 57 B M + + 0 8 7
22 PL 26 W F 0 0 3
28 PL 61 W M + + 0 0 4
29 PL 33 B F + + 200 8 6
30 PR, CY, C 41 H F + + 0 4 12
31 PL 82 W F 0 2 8
32 C 20 W F + 50 6 4
33 PL, M, PR 45 W F + 0 0 2
34 PL 23 W F + 0 8 5
35 PL, PR 47 W F + + 25 6 6
37 PL, PR 28 W F + 200 7 12
38 PL, PR 33 W M + 50 0 3
41 CY 34 W F + + 0 22 17
40 PR, A 37 B M + + 400 24 18
aEach Pts was assigned a unique number. bPts with a CD19hi population are indicated by a +. cMedications that each Pt was
taking at the time of blood draw are indicated: plaquenil (PL), cellcept (C), cytoxan (CY), prednisone (PR), azathioprine (A), and
methotrexate (M). dAge at the time of analysis is provided. eRace is indicated as American Indian (AI), black (B), Hispanic (H), or
white (W). fIndicates whether the Pt has glomerulonephritis. gIndicates whether a Pt has ever suffered a seizure or psychoses.
hIndicates the presence of anti-ssDNA, anti-dsDNA, or anti-Sm. iIndicates a positive ANA. jIndicates the titer of anti-Sm as
measured by ELISA (illustrated in Fig. 6). kSLEDAI and BILAG scores were determined at the time of B cell analysis(334, 335).
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Table 2.2. ANCA-SVV Patients.
IDa CD19hi b Medsc Gender Aged Racee Diseasef ANCAg ANCA
Titerh
Activityi BVASj
3 + C, CYC F 24 B MPA MPO 24.3 R 0
5 + CY,PR M 76 A MPA MPO 5.3 A 3
11a PR, A M 46 B WG PR3 3.5 R 0
11b + PR, A M 49 B WG PR3 120.5 R 0
16 + C, CYC F 38 W WG PR3 57.9 R 0
19 + PR F 63 W WG PR3 166 R 0
23a PR F 24 W WG PR3 13 A 8
23b + CYC F 25 W WG PR3 76.1 A 3
1 S M 50 W MPA MPO 68.6 A 12
2 None F 67 W MPA MPO 43.1 A 12
4a None F 28 W MPA MPO 75.9 R 0
4b None F 28 W MPA MPO 75 R 0
4c None F 29 W MPA MPO 69.9 R 3
6 PR, CYC, A M 49 W MPA MPO 7.3 R 0
7 None M 56 W GN MPO 29.5 A 6
8 S M 63 W MPA MPO 81.4 A 20
9a PR, A M 63 H MPA MPO 103 A 20
9b PR, A M 63 H MPA MPO 32 R 0
10 None M 66 W MPA MPO 71.4 R 0
12 CY, C F 63 W WG PR3 12O R 0
13a None F 52 B MPA PR3 172 A 6
13b A F 54 B MPA PR3 117 R 0
14 PR F 45 W WG PR3 78.4 R 1
15 PR, CYC, C M 57 W WG PR3 52 A 18
17 C M 23 W WG PR3 74.3 A 11
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aEach Pt was assigned a unique number. Serial numbers of the same Pt are indicated by letters. bPts with a CD19hi population are
indicated with a +. cMedications that each Pt was taking at the time of blood draw are indicated: plaquenil (PL), cellcept (C),
cytoxan (CY), cyclosporine (CYC), prednisone (PR), azathioprine (A), and solumedrol (S). dAge at time of analysis. eRace is
indicated as asian (A), black (B), or white (W). fDisease classification are indicated as Wegener’s granulomatosis (WG),
microscopic polyangitis (MPA), or pauci-immune necrotizing and cresentic glomerulonephritis without extra-renal manifestations
(GN). Pt 22 also has anti-glomerular basement membrane autoantibodies (GBM). gThe specificity of the ANCA (MPO or PR3)
is indicated. hANCA titer expressed in units/ml. A positive test corresponds to a titer >20u/ml. iPts are classified as being in
remission (R) or having active disease (A) based on clinical assessment and BVAS score. Pts with a BVAS score W1 are
considered in remission; Pts with a score >1 are considered active. BVAS was calculated by a standard protocol for vasculitis
activity score modified in 2003(353).
Table 2.2 Cont.
18 PR M 71 W WG PR3 158 A 20
20 None M 38 W WG PR3 116 R 0
21 S F 55 W WG PR3 171 A 27
22 None M 26 W MPA/GBM PR3 4 R 0
24 S M 77 W WG PR3 165 A 2
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Figure 2.1. Two B cell populations are detected in SLE and ANCA-SVV Pts based on 
CD19 expression and size (FSC).   
(A) Histograms of representative Pts and HCs.  Populations of smaller CD19lo and larger 
CD19hi B cells are indicated.  Two representative HCs, SLE Pts in which the majority of Pts 
that have only the CD19lo population (SLE), and SLE Pts that also have a CD19hi population 
(SLE CD19hi) are shown.  One representative ANCA-SVV Pt with and one Pt without a 
CD19hi population is shown.  Histograms represent >10,000 CD19+ lymphocytes.  Note that 
the CD19 staining intensities differ between Pt samples due to unavoidable day-to-day 
staining variation. (B) Comparison of CD19 expression between SLE and ANCA-SVV B 
cells with HCs analyzed on the same day.  The comparison is between the smaller CD19lo B 
cells from SLE and ANCA-SVV Pts and all CD19+ B cells from HCs stained on the same 
day.  Gates for this analysis are as in (A).  (C) The difference in CD19 MFI between CD19lo 
B cells of SLE and ANCA-SVV Pts and HC B cells.  Numbers were determined by 
subtracting the CD19 MFI of the HC B cells from the CD19 MFI of the CD19lo Pt B cells.  
Each symbol represents a HC/Pt comparison stained on the same day.  On average CD19lo 
SLE PB B cells stain ~18% less well for CD19 than HC B cells (indicated by the horizontal 
dotted line).  To control for medication in this analysis a group of 7 ANCA Pts not on 
medications at the time of analysis were compared separately.  Statistical significance was 
determined by the Wilcoxon’s signed-ranks test.  (D) CD38 and IgD staining of B cells from 
HCs and SLE/ANCA-SVV B cells to identify the Bm designation.  The subset descriptions 
and Bm designation are indicated.  Comparison is between all CD19+ B cells of a HC, and 
the CD19lo population from a SLE and ANCA-SVV Pt as gated in (A). 
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Figure 2.2. CD19hi B cells are present in a subset of SLE or ANCA-SVV Pts. 
(A and B) The frequency of CD19hi B cells in individual SLE and ANCA-SVV Pts.  Each 
symbol represents an individual Pt or HC.  CD19hi B cells were gated as in Fig. 2.1A.  The 
horizontal line indicates the frequency that is 2 standard deviations above the mean for HCs.  
Pts with a CD19hi B cell population above this point were considered positive for a CD19hi 
population.  (C) The difference in MFI between the CD19hi population, as gated in Fig. 
2.1A, and the HC B cells stained on the same day.  The difference was calculated as 
described in Figure 2.1C.  Each dot represents an individual Pt/HC comparison.  Statistical 
significance was determined by the Wilcoxon’s signed-ranks test.  (D) Analysis of 
representative SLE and ANCA-SVV Pts at one year intervals.  The SLE Pt had a CD19hi 
population on initial analysis that was evident at each subsequent visit, whereas the ANCA-
SVV Pt did not have a CD19hi population on their initial analysis, but did on a subsequent 
analysis.  The histograms are as described in Fig. 2.1A.  The frequency of CD19hi B cells, as 
gated, are given. 
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Figure 2.3. SLE and ANCA-SVV CD19hi B cells are primarily IgG+ IgD- memory B 
cells. 
(A) The percentage of IgD+ and IgG+ B cells is shown for each of the following cell 
populations for SLE (upper) and ANCA-SVV (lower) Pts: B cells from HCs, CD19lo B cells 
from Pts and without a CD19hi population (labeled SLE or ANCA-SVV), and CD19hi B cells. 
P values for the differences between CD19hi B cells and HC B cells were calculated by the 
Student’s t test and are shown.  (B) The expression of CD38 and IgD is shown to determine 
the subset identity of SLE and CD19hi B cells.  Total CD19+ B cells from a HC and the 
CD19lo and CD19hi B cells (as defined in Fig. 2.1A) from an SLE Pt are shown.  Similar 
results were obtained from ANCA –SVV Pts.  (C) The average percentage of cells belonging 
to the indicated subset from all SLE and ANCA-SVV Pts and HCs analyzed based on the 
subset identities indicated in B, except that the memory subset is the combination of early 
Bm5 and Bm5.  Error bars represent standard error.  * P <0.05 and ** P <0.001 (Student’s t 
test).  
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Figure 2.4. CD19hi B cells are somatically mutated and antigen selected. 
Single CD19hi B cells were sorted according to the gating shown in Fig. 2.1A.  (A) Percent 
VH family gene use by µ (N=20) and  (N=19) sequences is shown.  (B) Summary of 
somatic mutations of SLE CD19hi B cells are illustrated.  IgM and IgG sequences are shown 
separately.  The number of sequences with zero, 1-10, or >10 mutations is graphed. The 
number of sequences within each group is given.  (C) Shared independent mutations are 
shown from sequences encoded by the same gene.  The genes expressed are given and each 
mutation is identified with a vertical line.  Unshared mutations are not shown. 
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Figure 2.5. CD19hi B cells of SLE and ANCA-SVV Pts have upregulated activation 
markers.  
 Overlays of the indicated cell surface molecules from a HCs and CD19hi SLE Pt (top row) 
and ANCA-SVV Pt (bottom row).  For the Pt, the CD19lo and CD19hi B cells are shown 
separately.  The dashed line represents HC B cells, the thin solid line represents CD19lo B 
cells from the Pt, and the dark solid line represents CD19hi B cells from the Pt.  Histograms 
are representative of 3 or more Pts and HCs. 
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Figure 2.6. HC memory B cells have higher CD19 expression than naïve B cells.   
(A) CD19 expression on naïve B cells (IgD+ CD38+, dashed line) and memory B cells (IgD-
CD38lo/-, thin black line) from a representative HC (top panel), on naïve and memory B cells 
of an SLE Pt that does not have a CD19hi population (middle panel), and on naïve B cells 
(dashed line), CD19lo memory B cells (thin black line), and CD19hi memory B cells (thick 
black line) from an SLE and ANCA Pt with a CD19hi population (bottom panel) are shown.  
All samples were collected and stained on the same day.  Vertical lines mark the CD19 MFI 
of the HC memory B cells and are in identical positions in all three histograms.  (B) The 
average CD19 MFI of HC naïve and memory B cells (n=10).  The difference between the 
two populations is significant (P=3x10-5; Student’s t test).  
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Figure 2.7. CD19hi Pts have a distinct autoantibody profile.   
(A) CD19hi Pts have a significantly elevated anti-Sm titer compared to CD19lo Pts and HCs 
(P<0.01 for each comparison; Student’s t test).  Each symbol represents an individual Pt.  
The median titer for each group is marked by a horizontal line.  (B) IgG autoantibody 
profiles were determined from sera of HCs, CD19lo SLE Pts and CD19hi SLE Pts using 
autoantigen proteome arrays bearing 67 different nuclear or glomerular autoantigens, as 
previously described(341). Fluorescent intensities were normalized using human IgG 
standard and presented as normalized fluorescent intensity (nfi) units.  Each dot represents 
serum from an individual HC/Pt. Horizontal lines indicate group means.  Listed below the x-
axis are the student’s test P-values when CD19lo was compared to HC, or when CD19hi was 
compared to HC or to CD19lo, respectively (*, P < 0.05; **, P < 0.01; ns, not significant).  
The serum IgG levels for CD19lo and CD19hi Pts (Avg ± SD) were significantly different 
from HCs (P= 0.042 and 0.010, respectively, Student’s t test), but not from each other.  They 
were as follows:  HCs, 5.63 ± 1.26 mg/ml; CD19lo Pts, 8.64 ± 4.06 mg/ml; CD19hi Pts, 8.82 
± 5.01 mg/ml.  (C) IgM autoantibody levels against the same autoantigen proteome arrays as 
in (B).  Fluorescent intensities were normalized using human IgM standard and presented as 
nfi units. Each dot represents serum from an individual HC/Pt. Horizontal lines indicate 
group means.  The serum IgM levels were not significantly different by Student’s t test and 
are given as Avg ± SD: HC, 546 ± 224 µg/ml; CD19lo, 496 ± 346 µg/ml; CD19hi, 455 ± 396
µg/ml. 
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Figure 2.7, continued.
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CHAPTER 3: A UNIQUE SUBSET OF MEMORY B CELLS IS 
ENRICHED IN AUTOREACTIVITY AND CORRELATES 
WITH ADVERSE OUTCOMES IN SLE 
83
I. ABSTRACT 
 
We previously reported that a subset of systemic lupus erythematosus (SLE) patients 
have an expanded population of memory B cells with >2-fold increased expression of CD19 
(CD19hi).  We show here that the presence of CD19hi B cells correlates with long-term 
adverse outcomes, notably neurological complications and end stage renal disease, and with 
poor clinical responsiveness to treatment with rituximab.  B cells specific for the Smith (Sm) 
autoantigen are enriched in the CD19hi population, and this enrichment correlates with the 
serum anti-Sm titer.  Functional analysis and transcription factor expression suggests that 
CD19hi B cells are at an early stage in plasma cell differentiation and are not anergic.  
Interestingly, they have high basal levels of phosphorylated Syk and ERK1/2, indicating 
ongoing signaling, possibly through the B cell receptor complex.  They express high levels of 
CXCR3, but low levels of CXCR4 and CXCR5, and chemotax towards the CXCR3 ligand 
CXCL9, but not the CXCR4 ligand CXCL12, suggesting that they are homing to sites of 
inflammation rather than to the bone marrow.  We conclude that the CD19hi B cells are 
precursors to autoantibody producing plasma cells, and that this population identifies a subset 
of SLE patients likely to experience poor clinical outcomes.  
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II. INTRODUCTION 
 
Systemic lupus erythematosus (SLE) is a severe, autoantibody-mediated disease 
affecting multiple organ systems.  The etiology is poorly understood, but has both genetic 
and environmental components.  Because anti-nuclear antibodies (ANA) are pathogenic in 
this disease(331, 332), B cells are thought to play a pivotal role in its development and 
progression.  Apart from their role as producers of antibody, B cells may also mediate SLE 
development and pathogenesis through their actions as antigen presenting cells (APCs) and 
producers of cytokines(220, 230, 305, 332, 354-357).  Thus, understanding how B cell self-
tolerance is broken in SLE is important to the development of new therapeutic approaches. 
No unique precursors of autoantibody producing cells have been identified in SLE 
patients, suggesting that autoreactive cells are indistinguishable from cells recognizing 
foreign antigens.  Human autoantibodies are predominantly IgG and somatically mutated, 
suggesting that they are the product of germinal center responses.  Both class-switched (IgD-)
and IgM (IgD+) memory B cells have been described in human tonsil, spleen, and circulation, 
and are typically CD38- and CD27+, although CD27- subsets have been described(199, 200).  
CD19loCD38hi plasmablasts have also been identified in human blood, and both of these 
populations are relatively expanded in SLE patients(307, 315).  Upon re-encounter with their 
cognate antigen, memory B cells proliferate, after which some differentiate into plasma cells 
(PC) and others regenerate the long-lived memory population.   
B cell activation is dependent on multiple factors, including specificity and affinity 
for antigen, and the function of co-receptor molecules that act to amplify or dampen signals 
through the BCR.  Balance between these negative and positive modulators is important in 
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establishing B cell tolerance.  CD19 is a BCR co-receptor that augments BCR signaling and 
has become of significant interest in autoimmunity.  It is a component of a multimeric protein 
complex that includes CD21, CD81, and Leu-13(133).  It also serves as a signaling partner 
for other receptors, including CD21, CD40, CD38, CD72, VLA-4, and FcRIIB(132, 333, 
358-360).  CD19 is expressed by all B cells beginning at the pro-B stage, but is lost along 
with many other B cell-specific proteins upon plasma cell differentiation(358).  Alterations in 
CD19 expression by B cells affect their function and differentiation.  In the absence of CD19, 
B cells are hyporesponsive to BCR signaling and generate weak responses to T-dependent 
antigens with dramatically reduced germinal center formation; conversely, a high density of 
CD19 confers hypersensitivity to BCR signaling and vigorous immune responses(361, 362).  
In mice, as little as a 15% increase in CD19 expression induces a loss of B cell tolerance and 
autoantibody production(132, 152, 297). Thus, CD19 is critical to setting the threshold levels 
for the induction of B cell tolerance and activation.   
How CD19 functions in B cell activation has been intensely investigated. 
Crosslinking of CD19 or the BCR results in rapid phosphorylation of the cytoplasmic tail of 
CD19 leading to a processive amplification of Lyn phosphorylation(363).  Activated Lyn 
phosphorylates the immunoreceptor tyrosine-based activation motifs (ITAMs) on CD79a and 
CD79b, the signaling subunits of the BCR, which provides a binding site for the Src family 
tyrosine kinase Syk(85, 150, 363, 364).  Syk is a key protein tyrosine kinase in B cells, since 
the loss of Syk results in a block in further signaling downstream of the BCR and a block in 
B cell development(128, 129).  These initial events lead to the formation of a BCR 
signalsome, a complex of multiple protein tyrosine kinases and adapter proteins on the inner 
surface of the plasma membrane that induces in the release of intracellular Ca++ and the 
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activation of protein kinase C (PKC) and numerous downstream kinases.  This cascade leads 
to the activation of the mitogen-activated protein kinases (MAPKs) extracellular signal-
regulated kinase (ERK), c-JUN NH2-terminal kinase (JNK), and p38 MAPK(85), which 
induce the transcription of relevant genes.  The profile of the genes activated by MAPKs 
determines cell fate by controlling proliferation, survival, and differentiation.   
In addition to its role in Lyn phosphorylation, CD19 contributes to B cell activation 
by the recruitment phosphatidylinsoitol 3-kinase (PI3K) to the BCR.  Activated PI3K is 
critical to the release of intracellular Ca++ and PKC activation, and therefore MAPK 
activation, and to the activation of the Akt pathway, a B cell survival and metabolic fitness 
pathway.  CD19 signals also synergize with BCR signals by a mechanism independent of 
Ca++ and PKC to enhance the activation of the MAPK ERK1/2(151).  Thus, CD19 
contributes to B cell activation by inducing the activation of multiple pathways crucial to B 
cell function in response to antigen stimulation.  
Altered CD19 expression is evident in human autoimmunity.  Systemic sclerosis 
patients have a 20% increase in CD19 expression(297), while SLE patients have decreased 
CD19 expression compared to healthy control B cells(296, 297, 365).  In addition, we, and 
others, have shown a population of B cells which have 2-3 fold increased levels of CD19 
compared to other B cells from the same patient or to HC B cells(CD19hi cells) in SLE, 
ANCA-SVV, and CVID patients(283, 298, 365).  We previously reported that these CD19hi 
B cells have an activated memory phenotype, are class switched, and show evidence of 
antigen selection(365).  We propose that the increased CD19 expression on CD19hi memory 
B cells decreases their activation threshold leading to enhanced proliferation, survival, and 
plasma cell differentiation.  If the CD19hi memory B cell subset contains autoreactive B cells, 
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then a lower threshold of activation may lead to chronic activation and production of 
autoantibody producing plasma cells.   
Herein we show that the CD19hi population is enriched in autoreactive B cells, and 
that the degree of enrichment correlates with autoantibody titers.  Consistent with increased 
autoreactivity, their presence correlates with poor clinical outcomes and with a poor clinical 
response to B cell depletion by rituximab.  Analysis of these cells suggests that they are at an 
early stage in plasma cell differentiation, are not anergic, and are likely to be homing to sites 
of inflammation rather than the bone marrow.  Thus, CD19hi B cells appear to constitute a 
population unique to autoimmunity that contribute to autoantibody production and that may 
play a pivotal role in disease pathogenesis. 
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III. MATERIALS AND METHODS 
 
HC and Pt Clinical Samples and Data 
PB samples were collected from 10 HCs (mean age: 36.5 yrs, range: 27-54, gender: 8 
female, 2 male) and 10 Pts (mean age: 37 yrs, range: 23-53, gender: 10 female); in some 
cases, the same HC or Pt was used in multiple occasions or experiments.    Five of the 10 Pts 
from this study were patients continuing from the original study(365), and the other five were 
newly identified.  Pts were included in this study after informed consent in accordance with 
our institutional internal review board, and fulfilled at least four of the established American 
College of Rheumatology 1997 revised criteria for SLE.  Samples were gathered during 
routine clinic visits, and sera obtained from the same blood draw as that for B cell analysis. 
Table 1 is a prospective analysis of clinical outcomes of patients remaining in our 
study since the previous publication(365) and details such as their medications can be found 
in that manuscript.  Clinical outcomes were determined by review of patient records. 
PB samples were collected into Vacutainer CPT tubes with sodium heprin (BD 
Biosciences) and sera and PBMCs isolated as per manufacter’s protocol.  PBMCs were 
washed once with sterile PBS before continuing with any protocol. 
 
Flow Cytometry, Signaling Studies, and FACS 
 For surface staining, cells were prepared and stained as previously reported(365). 
Signaling and phosphoprotein studies were carried out using the BD Phosflow system as per 
manufacturer’s Protocol 1 (BD Biosciences, San Diego, CA). Briefly, cells were resuspended 
at 2.5x106 cells/mL in RPMI + 2% FBS and equilibrated at 37°C for at least 20 min.  An 
equal volume of pre-warmed, 2x solution of goat F(ab’)2 -human IgG (10ug/mL final, 
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Southern Biotech, Birmingham, AL) or Pansorbin (0.1% final, Calbiochem, La Jolla, CA) 
was then added with vortexing, and cells were returned to 37°C for 10 min.  Cells were then 
immediately fixed by addition of pre-warmed Phosflow Fix Buffer 1, and Protocol 1 
followed for permeabilization and staining.  Antibodies used were: pSyk-PE, pERK-PE, Syk-
FITC, pan ERK, pJNK, p-p38-FITC, Ki-67-FITC, CD19-APC, CD20-PE and -APC-Cy7, 
and CD72-FITC (BD Biosciences, San Diego, CA); pAkt (Thr308) and pAkt (Ser473)-
Alexa488 (Cell Signaling Technology, Boston, MA); CD180-PE (RP105), BR3-FITC, 
TLR4-PE, and TLR9-PE (eBioscience, San Diego, CA).  Unlabeled antibodies were labeled 
using Zenon technology (Invitrogen, San Diego, CA).  Appropriate pre-labeled or Zenon 
labeled isotype controls were used in each experiment. 
For PI staining, 5x105 cells were aliquoted, washed with cold PBS, resuspended in 
0.5mL cold PBS and permeabilized with 4.5mL ice cold 70% ethanol for 2 hrs at -20°C.  
Cells were then pelleted, washed with cold PBS, and resuspended in 750uL of a solution with 
0.2 mg/mL RNase A, 0.02 mg/mL propidium iodide (PI), 0.1% Triton X-100 (all from 
Sigma-Aldrich, St. Louis, MO) and CD20-FITC (cytoplasmic domain, from BD 
Pharmingen, San Diego, CA) in PBS and incubated for 1 hr on ice.  Cells were then washed 
with PBS and analyzed by flow cytometry. 
For FACS, cells were prepared as described above and stained on ice with some or all 
of the following, depending on the experiment: CD19-APC, CD20-APC-Cy7, IgD-FITC, and 
CD38-PE-Cy7 (BD Pharmingen, San Diego, CA).  Cells were sorted using settings to obtain 
maximum purity on one of two high-speed sorters (MoFlo, Dako Cytomation or FACSAria, 
BD Biosciences).  Post-sort analysis determined purity of populations at >90%. 
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RNA Extraction and Real Time PCR 
Sorted cell populations were spun down, supernatant removed, and frozen at -80°C 
until RNA extraction using RNeasy mini columns (Qiagen, San Deigo, CA) as per 
manufacturer’s protocol.  The reaction for generation of cDNA was carried out using a poly-
A primer and SuperScriptII Reverse Transcriptase (Invitrogen, San Diego, CA) according to 
manufacturer’s protocol. 
Real time PCR was carried out using TaqMan Gene Expression Assays, with -Actin 
as an endogenous control, as per manufacturer’s protocol (Applied Biosystems, Foster City, 
CA) on an ABI Prism 7000 Sequence Detection System machine.  Data were analyzed using 
ABI Prism 7000 software relative quantification study parameters.  In each case, transcript 
expression, normalized to -actin expression, in CD19hi cells is quantified relative to 
expression in CD19lo cells from the same Pt. 
 
ELISpot 
 Anti-Sm and anti-IgG ELISpot protocols were adapted from those used in this lab for 
mouse B cells(232). Briefly, 96-well filter plates were coated with diluted Sm protein 
(Immunovision, Springdale, AZ) or anti-human IgG (Bethyl Laboratories, Montgomery, 
TX).  Sorted cells were resuspended in DMEM supplemented with 10% FBS, 100U/mL 
Penicillin/Streptomycin (Gibco Invitrogen, San Diego, CA), 0.1% -mercaptoethanol (Gibco 
Invitrogen, San Diego, CA), and 40ug/mL transferrin (BD Biosciences, San Diego, CA) and 
plated between 5x104 and 6x105 cells in 200uL/well either without stimulation or stimulated 
with 15ug/mL anti-CD40, 100U/mL rhIL-2, 100U/mL rhIL-10, (BD Pharmingen, San Diego, 
CA), and 0.01% Pansorbin (Calbiochem, La Jolla, CA) as previously described for maximal 
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stimulation of antibody secretion(366).  In each plate, CD19hi and CD19lo cells, stimulated 
and unstimulated, were plated on both Sm and IgG coated wells and incubated for 6 days at 
37°C with 5% C02. They were then washed as previously described and incubated with an 
anti-human IgG-HRP antibody (Bethyl Laboratories, Montgomery, TX) overnight at 4°C. 
The plates were then developed and read as previously described(232). Counts were 
normalized to spots per million cells based on the number of cells plated in that well. 
 
Elisas 
The sCD21 Elisa was carried out with frozen serum samples from the Pts and HC 
analyzed in our previous study(365) using a sCD21 Elisa kit (Cell Sciences, Canton, MA) 
according to manufacturer’s protocol. 
The -Sm Elisa was carried out as previously described(365) using serum samples 
obtained from the same draw as the cells sorted and plated in ELISpot. All four Pt samples 
were run on the same plate. 
 
Chemotaxis Assay 
Chemotaxis assays were performed as previously reported for human PB B 
cells(211).  Briefly, 5uM pore size transwell inserts (Costar, Corning, NY) were coated with 
human fibronectin (Sigma-Aldrich, St. Louis, MO) and washed.  100\L of 5x106 cells/mL 
purified PBMCs in RPMI 1640 (Gibco, Invitrogen, San Deigo, CA) with 0.5% BSA (Sigma-
Aldrich, St. Louis, MO) were added to the upper well and 600\L of media alone or with the 
appropriate chemokine were added to the lower well.  Chemokines used were CXCL9/MIG 
at 10nM and CXCL12/SDF-1 at 100nM (R&D Systems, Minneapolis, MN). Plates were 
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incubated at 37°C in 5% CO2 for 90 minutes and migration assessed by staining and flow 
cytometry of cells in upper and lower wells. 
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IV. RESULTS 
 
The presence of CD19hi B cells correlates with adverse clinical outcomes.
We previously reported that the presence of CD19hi B cells did not correlate with 
disease activity or any specific feature of SLE except for severe neurological dysfunction 
(seizures or psychoses), which was seen in 2 of 14 CD19hi SLE patients and none of 27 
CD19lo SLE patients(365).  We have now followed the same patient cohort over a five-year 
period to determine whether there is a correlation with long-term clinical outcome.  As seen 
in Table 1, the presence of a CD19hi population was again significantly associated with 
severe neurological involvement, as two additional CD19hi SLE patients developed this 
complication, whereas none of the CD19lo SLE patients exhibited neurological symptoms.  In 
addition, there was a significant correlation with end stage renal disease (ESRD), and overall 
presence of any one of four adverse outcomes (severe neurological complications, ESRD, 
thrombic thrombocytopenic purpura (TTP), or death due to disease complications).  Taken 
together, these findings suggest that presence of the CD19hi memory population identifies a 
subset of SLE patients that are likely to develop more severe disease, and suggests that these 
cells play a role in neurologic and renal pathogenesis. 
 
CD19hi patients respond poorly to rituximab.  
 
Given the increased frequency of severe complications among CD19hi patients, we 
determined how these patients responded clinically to B cell depletion therapy with 
rituximab, a humanized anti-CD20 monoclonal antibody.  In SLE, the response to rituximab 
is variable; some patients experience long-term clinical remission, while others experience 
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short-term remission or no clinical response(315, 321, 367).  In a survey of 17 SLE patients 
treated with rituximab, five possessed a CD19hi population either before or after treatment 
with rituximab based on having a frequency of CD19hi B cells that exceeded two-times the 
standard deviation above the mean percentage in healthy controls.  Clinical response to 
rituximab was defined as an improvement in the SLAM or SLEDAI of at least 3.  Clinical 
response duration was defined as the time point where these disease activity indexes began to 
increase (relapse occurred), with the SLAM and/or SLEDAI increasing by at least 3 points 
and/or an increase in steroids required.  As shown in Fig. 1, four CD19hi patients were short-
term responders to rituximab (9 months or less), and one was a non-responder.  In contrast, 
almost half (5 of 12) of CD19lo patients experienced a 12-month or longer remission, and of 
these, three had an extended, ongoing clinical response to rituximab treatment.  The 
remaining seven were short term or non-responders to treatment.  Thus, rituximab may be a 
less efficacious treatment for SLE patients with an expanded CD19hi population than for SLE 
patients that lack this population. 
 
The CD19hi population is enriched in autoreactive B cells.  
 
To determine whether CD19hi B cells can contribute to autoantibody production, we 
tested whether the CD19hi population is enriched in autoreactive B cells.  Since the presence 
of a CD19hi population is strongly associated with a high anti-Smith (Sm) serum titer(365), 
we measured the frequency of anti-Sm IgG B cells in the CD19hi and non-CD19hi (CD19lo)
populations by ELISpot.  We sorted CD19hi and CD19lo B cells from four SLE patients, three 
of whom had elevated anti-Sm titers, and induced ASC differentiation with pansorbin, anti-
CD40, IL-4, and IL-10 for 6 days on ELISpot membranes coated with purified Sm protein.  
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No anti-Sm antibody secreting cells were observed among the CD19hi or CD19lo B cells from 
the patient that lacked an anti-Sm titer.  However, significantly more anti-Sm IgG secreting 
cells were present among CD19hi B cells than among CD19lo B cells (p=0.01, Fig. 2A) from 
the remaining three patients.  Importantly, the frequency of anti-Sm ASCs within the CD19hi 
population correlated exponentially with the serum anti-Sm titer (R2=0.99 and R2=0.4, 
respectively, Fig. 2B).  Since a two-fold increase in anti-Sm B cell frequency within the 
CD19hi compartment is associated with an ~100-fold increase in serum anti-Sm, not only are 
CD19hi cells likely to be direct precursors to autoantibody secreting plasma cells, but they are 
likely to clonally expand before differentiating, and may also play a role in skewing the 
immune response towards particular autoantigens, such as through activation of cognate T 
cells. 
 
CD19hi cells have a unique basal phosphorylation state. 
To determine whether increased CD19 alters BCR signaling, we measured basal and 
BCR stimulated levels of phosphorylated signaling molecules.  We compared the levels of 
phosphorylated CD19, Syk, Akt, and the MAPKs ERK1/2, JNK, and p38 in CD19hi B cells 
with those of CD19lo B cells from the same patient and healthy control (HC) B cells.  To 
detect phosphorylated proteins in these cells we used flow cytometry, since the limited 
numbers of CD19hi B cells that can be obtained precluded the use of standard western 
blotting methods.  Flow cytometry had the added benefit of also determining the frequency 
of B cells within a population that exhibited increased phosphorylation of a given protein.   
 To measure basal phosphorylation levels of these proteins, we stained for their 
presence immediately following purification of peripheral blood monocytes (PBMCs).  In 
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each case a HC blood sample was stained at the same time. There was a modest but 
significant increase in CD19 phosphorylation (pCD19) in CD19hi B cells compared to 
CD19lo (average=1.5 fold), but the increase in total CD19 expression was significantly 
greater (average=2.9 fold, Fig. 3A).  Thus, a smaller proportion of CD19 was phosphorylated 
in CD19hi B cells compared to CD19lo cells.  Because CD19 phosphorylation amplifies Syk 
activation(131), we were surprised to find that despite a lower frequency of CD19 
phosphorylation, nearly all CD19hi B cells displayed significantly elevated levels of 
phosphorylated Syk (pSyk) compared to the CD19lo B cells from the same patient and from 
HC B cells (Fig. 3B-D).  The median fluorescence intensity (MFI) of pSyk was ~3.2-fold 
greater than that for CD19lo B cells from the same patient.  Likewise, nearly all CD19hi B 
cells exhibited significantly elevated levels of pERK1/2 than CD19lo B cells from the same 
patient and from HC B cells (Fig. 3B-D).  CD19hi B cells had a MFI of pERK1/2 that was 
~2.9-fold greater than CD19lo B cells from the same patient.  Levels of total Syk 
(average=1.8 fold) and ERK (average=1.4 fold) protein were also elevated in CD19hi as 
compared to CD19lo B cells (Fig. 3C and D), but they were significantly lower than increases 
in pSyk and pERK1/2 levels (Fig. 3D).  It should be noted that the pan-ERK antibody 
recognizes other ERK family members in addition to ERK1/2, and therefore the increased 
ERK levels detected by this antibody may have overestimated the increase in ERK1/2 levels.  
In contrast to Syk and ERK, we observed no significant increases in basal phosphorylation 
levels of Akt or the MAP kinases p38 or JNK.  In the case of Akt, no increase in 
phosphorylation was detected at either phosphorylation site (Fig. 3D).  Thus, ex vivo CD19hi 
B cells exhibit an unusual phenotype.  Despite a lower frequency of phosphorylated CD19, 
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nearly all cells exhibiting increased levels of pSyk and pERK1/2, but not increased 
phosphorylation of other MAPKs or Akt downstream of the BCR and CD19.  
 
CD19hi B cells are responsive to BCR stimulation. 
Since constitutively elevated pERK levels are associated with B cell tolerance(240), 
we sought to determine whether crosslinking the BCR on CD19hi B cells results in 
transduction of signal and plasma cell differentiation.  To determine whether BCR signaling 
is intact in CD19hi B cells, HC and SLE B cells were stimulated with anti-IgG or pansorbin 
for 10 minutes and the levels of phosphorylated molecules determined by flow cytometry.  
Although the kinetics of phosphorylation may vary for each molecule examined, we sought a 
time point at which phosphorylation of all measured molecules could be observed in HC and 
SLE B cells due to limitation of cell number,  All five signaling intermediates and CD19 
were phosphorylated upon BCR stimulation in HC B cells and SLE CD19lo B cells (Fig. 4A-
C), although a somewhat higher percentage of CD19lo B cells than HC B cells 
phosphorylated these molecules (Fig. 4C) consistent with reports that SLE B cells are 
hyperresponsive to BCR stimulation(300-302, 304, 365).  Importantly, SLE CD19hi B cells 
increased the levels of phosphorylated CD19, p38, JNK, and Akt similarly to HC and CD19lo 
cells (Fig. 4A and B).  The frequency of CD19hi B cells that increased the levels of each 
phosphorylated protein was similar to that of CD19lo and HC B cells (Fig. 4C).  In contrast, 
SLE CD19hi B cells exhibited little or no increase in the already high basal levels of pSyk 
and pERK1/2 (Fig. 4A and B), or in the percentage of cells positive for pSyk and pERK1/2 
(Fig. 4C).  Interestingly, the basal pSyk and pERK1/2 levels in CD19hi B cells were similar 
to those reached by HC and SLE CD19lo B cells after BCR crosslinking, suggesting that ex 
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vivo CD19hi B cells have already maximally phosphorylated these molecules.  Altogether, 
these data indicate that CD19hi B cells are not refractory to BCR signaling.  
To determine whether CD19hi B cells can be activated to become ASCs, we 
determined the frequency of IgG antibody-secreting cells by an ELISpot assay before and 
after stimulation.  As shown in Fig. 4D, an average of only 0.05% (SEM 0.03%) of CD19hi 
cells spontaneously secreted IgG, ~7-fold less than CD19lo B cells (0.34%, SEM 0.16%).  
However, stimulation with pansorbin, anti-CD40, IL-4, and IL-10, a cocktail previously 
shown to induce robust IgG secretion in memory cells(366), induced an average of 14.6% 
(SEM 4.51%) of CD19hi B cells to secrete IgG, nearly twice that seen with CD19lo B cells 
(7.9%, SEM 2.6%).  This may be de to differences in the frequency of IgG+ B cells in each 
population or to an increased propensity of CD19hi B cells to become antibody-secreting 
cells.  Thus, the ability of CD19hi B cells to signal in response to BCR ligation and their 
ability to differentiate to antibody-secreting cells upon stimulation suggests that CD19hi B 
cells are not anergic. 
 
CD21 expression is downregulated in CD19hi cells.
We previously reported the CD21 expression was decreased on the cell surface of 
CD19hi B cells, while CD21 levels were similar between HC B cells and SLE CD19lo B cells 
(Fig. 5A)(365).  Since CD19 is the signaling component for the complement receptor CD21, 
we wished to determine if this decreased surface expression was due to increased recycling, 
cleavage, or downregulation.  In some settings, CD21 is cleaved from the surface of activated 
B cells, forming soluble CD21 (sCD21) which can be detected in serum and in culture 
supernatants(284, 368).  We therefore compared CD21 transcript levels in sorted CD19hi 
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cells relative to CD19lo B cells from the same patient using relative quantification (RQ) real 
time PCR (RT-PCR).  CD21 transcripts were significantly decreased in all three patients 
examined (average RQ=0.16, Fig. 5B), suggesting downregulation, and not increased 
recycling or cleavage, is responsible for decreased CD21 expression by these cells.  
Consistent with this, although analysis of serum samples from the large cohort of CD19hi 
patients indicates that CD21 levels were lower in CD19hi patients compared to CD19lo 
patients and HCs, they were not statistically different (averages of 15.5U/mL, 21.6U/mL 
23.2U/ml, respectively).  However, sCD21 levels were significantly lower among SLE 
patients that had an elevated anti-Sm titer (Fig. 5C), in contrast to the previously reported 
general decrease in sCD21 among SLE patients compared to HCs(285).     
 
CD19hi cells have a pre-plasma cell transcription profile. 
Our previous analysis suggested that CD19hi B cells are activated memory B cells.  
However, the relationship between autoreactive B cell frequency and serum autoantibody 
titers suggests a close relationship between these cells and the plasma cell pool in these 
patients.  Thus, we sought to determine whether these cells were at an early stage in plasma 
cell differentiation by measuring the levels of B cell- and plasma cells-specific transcription 
factors by RQ RT-PCR.  RNA from sorted CD19hi and CD19lo B cells from three patients 
was used to determine expression levels of the B cell-specific transcription factors Pax-5 and 
Bcl-6, and the plasma cell-specific transcription factors Blimp-1, IRF-4 and XBP-1.  During 
differentiation to an ASC, Pax-5 and Bcl-6 are downregulated, and IRF-4, Blimp-1, and 
XBP-1 are upregulated(369).  As shown in Fig. 6A, CD19hi B cells showed significant 
downregulation of Pax-5 and smaller but consistent downregulation of Bcl-6 compared to 
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CD19lo B cells (average RQ=0.34 and 0.49, respectively).  However, they showed no 
upregulation of Blimp-1, IRF-4, or XBP-1 expression (Fig 6A).  Since >70% of CD19hi cells 
are IgD-CD38-(365), we sorted IgD-CD38- memory B cells with all other CD19+ B cells 
from three HCs is presented in Fig. 6B.  No significant differences were observed between 
the cells of these populations, including in Pax-5 expression (average RQ=1.4).  Thus, the 
low Pax-5 levels seen in CD19hi B cells are not a general characteristic of memory B cells, 
suggesting that CD19hi cells are at an early pre-plasma differentiative stage.   
Since our findings indicate that CD19hi B cells may clonally expand before becoming 
plasma cells, we determined whether they were actively undergoing cell division.  As 
expected, CD19hi B cells were not actively undergoing cell division.  As shown in Fig. 6A 
and Table 2, CD19hi B cells did not express high levels of Ki-67, a protein present only in 
proliferating cells, or exhibit an increase in DNA content, as measured by PI staining.  Thus, 
CD19hi cells are not in S phase.  However, CD19hi B cells consistently exhibited a small 
(average 1.7 fold) increase in Ki-67 staining (Table 2), consistent with cells in G1 phase or 
are just entering or leaving S phase(370, 371).  Thus, CD19hi B cells are not actively 
undergoing cell division, indicating the clonal expansion that they undergo before becoming 
plasma cells occurs after they exit the circulation.   
 
CD19hi B Cells have an unusual chemokine receptor expression profile. 
Long-lived plasma cells reside primarily in the bone marrow, and thus to determine 
whether the CD19hi B cells are likely to be homing to the bone marrow, we compared the 
transcript levels of CXCR4 and CXCR5 in CD19hi vs. CD19lo cells.  CXCR5 retains cells in 
the follicles of secondary lymphoid tissues, and is normally downregulated during plasma 
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cell differentiation, while CXCR4 is responsible for directing plasma cell precursors to the 
bone marrow and is normally upregulated during plasma cell differentiation.  As shown in 
Fig. 7A, CXCR4 transcripts were significantly lower in CD19hi B cells of all three patients 
(average RQ=0.1), as were CXCR5 transcripts in two of the three patients (average RQ=0.36, 
overall average RQ=0.7).  Similar to CD19hi B cells, HC memory B cells had lower 
transcript levels of CXCR4 and CXCR5 compared to non-memory B cells (average RQ=0.4 
and 0.7, respectively, Fig. 7B).  CXCR5 transcripts were similarly decreased in CD19hi and 
HC memory B cells relative to their respective controls (Fig. 7A and B).  However, the 
relative decrease in CXCR4 transcripts by CD19hi B cells was ~4 times greater than that in 
HC memory B cells (Fig. 7A and B).  We conclude that CD19hi B cells are unlikely to be 
homing to the bone marrow.   
Since CD19hi B cells are unlikely to be homing to the bone marrow, we determined 
whether CD19hi B cells could be homing to sites of inflammation.  CXCR3 levels are 
elevated on a subset of memory B cells and plasma cells(190, 194, 211), in addition to T 
cells(192), and directs migration sites of inflammation where CXCR3 ligands are present at 
high concentrations(194).  As seen in Fig. 7A, CXCR3 transcript levels were dramatically 
higher in CD19hi B cells compared to CD19lo B cells of all three patients tested (average 
RQ=14.2, range= 7.6-24).  CXCR3 transcripts were higher in HC memory B cells compared 
to non-memory B cells, but this increase was only ~2-fold (Fig. 7B).  This increase in 
transcript levels also results in a significant increase in CXCR3 protein on the cell surface of 
CD19hi B cells (Fig. 7C).  These results suggest that CD19hi B cells are homing to sites of 
inflammation. 
102
To confirm that increased expression of CXCR3 by CD19hi B cells is functionally 
significant, we determined the ability of CD19hi B cells to migrate in response to CXCR3 and 
CXCR4 ligands. As shown in Fig 7D, CD19hi B cells migrated efficiently in response to the 
CXCR3 ligand CXCL9, but not in response to the CXCR4 ligand CXCL12 or to media 
alone.  These data affirm that CD19hi B cells are unlikely to migrate to the bone marrow and 
indicate that the increased expression of CXCR3 on these cells is functionally relevant, 
supporting the idea that CD19hi B cells are homing to sites of inflammation. 
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V. DISCUSSION 
 
CD19hi B cells are a novel population of memory B cells that are expanded in a 
subset of SLE and ANCA-vasculitis patients(365).  We show here that in SLE, these B cells 
are a functionally and phenotypically distinct from HC memory B cells and appear to 
contribute to the autoantibody secreting plasma cell pool.  Presence of an expanded CD19hi B 
cell population may delineate patient subgroups within these diseases, as these patients are 
more likely to develop neurological problems and end stage renal disease, and to show poor 
clinical response to rituximab treatment.  These findings have implications for our 
understanding of autoreactive B cells in SLE and for the development of new therapies.  
Relevance of CD19hi B cells to autoimmunity is indicated by our finding that this 
population is enriched 3- to10-fold in anti-Sm B cells compared to the CD19lo population, 
and that this enrichment correlates with the level of serum anti-Sm antibody.  In contrast, the 
frequency of anti-Sm CD19lo B cells is not different between patients with varying degrees of 
anti-Sm titer elevation.  CD19hi B cells are unlikely to be anergic, as BCR crosslinking 
induces phosphorylation of CD19, Akt, JNK and p38 to levels comparable to those in CD19lo 
B cells from the same patient and to HC B cells.  Moreover, BCR signaling in conjunction 
with a CD40 signal and stimulation with IL-4 and IL-10 induces CD19hi IgG B cells to 
become antibody-secreting cells. 
Since CD19hi B cells are present above background in only 25-30% of SLE patients, 
we presume that anti-self memory B cells are not limited to this population.  However, our 
data suggest that the majority of anti-Sm B cells in the peripheral blood are CD19hi and 
therefore B cells specific for a given self-antigen may segregate to either the CD19hi or non-
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CD19hi memory B cell populations, rather than being present in both.  We reported 
previously that elevated frequencies of CD19hi B cells are associated with increased levels of 
autoantibodies against certain self-antigens, in particular small nuclear ribonucleoprotein 
(snRNP) antigens(365), suggesting that B cells specific for these autoantigens are also 
enriched in the CD19hi population.   
 Our data indicate that a doubling of the anti-Sm B cell frequency in the CD19hi 
population is associated with a ~100-fold increase in the serum anti-Sm titer, a relationship 
which cannot be accounted for by clonal expansion of CD19hi cells alone.  This finding is 
particularly impressive given the overall small number of CD19hi B cells present in the blood 
(typically <1% of PBMC).  Therefore, we hypothesize that CD19hi cells (1) are responsible 
for the majority of serum anti-Sm antibody, (2) clonally expand before differentiating into 
anti-Sm ASCs, and (3) also play a role in the amplification of the immune response to Sm, 
possibly through activation of cognate T cells.  This is an intriguing idea given our previous 
finding that CD19hi cells have increased surface MHCII and CD86 expression(365) and may 
therefore be highly efficient T cell activators. 
Our analysis of basal phosphorylation levels of signaling intermediates, transcription 
factor expression, and chemokine receptor expression support the hypothesis that CD19hi B 
cells are actively migrating to the tissues and undergoing plasma cell differentiation.  CD19hi 
B cells have high basal levels of pSyk and pERK1/2, equivalent to those in CD19lo and HC B 
cells after strong BCR crosslinking (Fig. 4B), suggesting that they have recently received an 
activating signal.  Since Syk phosphorylation is believed to be BCR/CD19 specific, it is 
likely that these cells have received a recent BCR/CD19 signal.  Syk and ERK 
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phosphorylation in BCR stimulated human IgG B cells are normally sustained for more than 
two hours(372), suggesting a possible time frame for the receipt of this activating signal.   
The absence of elevated basal levels of pAkt in CD19hi B cells seemingly contradicts 
the involvement of a BCR signal, since BCR signals induce Akt phosphorylation(149).  The 
main pathway for both ERK1/2 and Akt phosphorylation is the recruitment of 
phosphatidylinositol 3-kinase (PI3K) to the BCR complex by CD19 and its activation by 
Syk(85, 373, 374).  Thus, the phosphorylation of Syk and ERK1/2 suggests that the 
Syk/PI3K/ERK pathway is active.  Our findings could be explained in several ways.  Akt 
phosphorylation may be more transient than ERK or Syk(149) and thus, evidence of Akt 
phosphorylation may be lost before the cells can be analyzed.  Alternatively, Akt 
phosphorylation may be regulated downstream or independently of PI3K activation in 
response to the signal received by CD19hi B cells.  Indeed, Li and Carter(151) have 
demonstrated that that CD19 signals synergize with BCR signals to induce ERK1/2 
activation at a point downstream of PI3K in B cells.  Since Syk phosphorylation is also 
downstream of CD19 phosphorylation, this could explain the high levels of pSyk in these 
cells as well. 
MAP kinases are intimately involved in cell fate decisions regarding proliferation, 
apoptosis, and differentiation, and the activation of different combinations of MAP kinases 
may result in different biological outcomes(375).  Of the three MAP kinases examined, 
ERK1/2, JNK, and p38, only basal pERK1/2 levels were elevated in CD19hi B cells.  In the 
WEHI-231 B lymphoma cell line, BCR signaling preferentially activates ERK1/2, and only 
weakly activates JNK and p38, whereas CD40 signaling preferentially activates the JNK and 
p38 MAP kinases and does not activate ERK1/2(376).  Thus, the pattern of MAPK activation 
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in CD19hi B cells is congruent with these cells having recently received a BCR signal.  ERK 
MAP kinases are involved in regulating cell proliferation(375), and the elevated levels of 
pERK1/2 are consistent with our proposal that CD19hi B cells proliferate before plasma cell 
differentiation.  The absence of increased pJNK and pp38 levels in CD19hi B cells may 
indicate that they have not received a recent CD40 signal.  This could indicate that rather 
than being of direct germinal center origin, they are memory B cells that have been 
reactivated in the absence of T cell help.  A better understanding of the signals that result in 
this pattern of MAP kinase activation would aid in illuminating the nature of the activating 
signals received by CD19hi B cells.   
The low Pax-5 expression by CD19hi B cells suggests that CD19hi B cells are at an 
early stage of plasma cell differentiation.  This level of Pax-5 expression is not a 
characteristic of memory B cells in general, since HC memory B cells express levels of Pax-5 
that are not different from non-memory B cells (Fig. 6B).  Pax-5 is required for B cell 
differentiation and activates the expression of genes that maintain B cell identity(369), 
including CD19.  Thus, the low levels of Pax-5 expression by CD19hi B cells suggest that 
these cells are moving away from a B cell identity.  In addition, although CD19hi and CD19lo 
B cells have similar transcript levels of XBP-1, a transcriptional activator required for plasma 
cell differentiation, HC memory B cells express considerably less XBP-transcript levels than 
control B cells, suggesting that XBP-1 has increased in CD19hi B cells.  Since Pax-5 
represses the expression of XBP-1(377), increased XBP-1 may follow from the decreased 
expression of Pax-5.  We did not observe evidence of increased Blimp-1 transcript levels, 
and since transcription of PDRM1, the gene for human Blimp-1, is repressed by Bcl-6(177), 
this is consistent with the normal expression of Bcl-6 by CD19hi B cells.  Although Blimp-1 
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is required for full plasma cell differentiation and antibody secretion, it is not required for 
plasmablast or pre-plasma cell formation.  Blimp-1 represses the expression of a number of 
genes that are responsible for cell division(378), and thus the absence of increased Blimp-1 
expression is compatible with the hypothesis that CD19hi B cells undergo multiple rounds of 
cell division before differentiating to plasma cells.  It is important to keep in mind that these 
measures are relative to CD19lo cells from the same SLE patient (or non-memory B cells for 
HCs). Thus, differences in the frequency of plasmablasts between patients and HCs would 
tend to inflate the control levels of plasma cell-specific transcripts and diminish the control 
levels of B cell-specific transcripts.  An increase in plasmablasts in the peripheral blood of 
SLE patients and other autoimmune disease has indeed been reported(283, 315, 379).  Single 
cell RT-PCR analysis should clarify this issue, and is underway.  
Chemokine receptor expression further supports the hypothesis that CD19hi B cells 
are undergoing plasma cell differentiation.  CD19hi B cells from two of the three patients 
examined had less than half of the CXCR5 transcript levels seen in CD19lo B cells from the 
same patient.  This is consistent with activation, and could account for their presence in 
peripheral blood.  However, it would not appear that these cells are migrating to the bone 
marrow, a prominent location for long-lived plasma cells.  CXCR4 transcripts, which are 
typically increased during plasma cell differentiation(380), are ~10% of the level present in 
CD19lo cells, and CD19hi B cells are not responsive to the CXCR4 ligand CXCL12.   
A more likely destination for CD19hi B cells are sites of inflammation, guided by high 
levels of CXCR3.  CXCR3 transcripts are ~14-fold higher in CD19hi B cells than in control 
CD19lo B cells, a finding that is reflected by an increase in CXCR3 surface expression.  
CXCR3 on these cells is functional, as they chemotax in response to the CXCR3 ligand 
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CXCL9.  A subset of human memory B cells and plasmablasts express CXCR3, and the 
expression of this chemokine receptor is maintained after plasma cell differentiation(190, 
194, 211).  The CXCR3 ligands CXCL9, CXCL10 and CXCL11 are highly expressed in 
peripheral sites of inflammation, where, in autoimmunity and other highly inflammatory 
states, B cells can differentiate to tissue-resident plasma cells(190, 193, 194, 381, 382).  For 
example, CXCR3 ligands are elevated in the skin of patients with cutaneous lupus(383), the 
synovium of RA patients(193), and the kidney and serum of SLE patients(384-386).  
Interestingly, CXCR3 ligands are elevated in the CNS of SLE patients with neurological 
involvement(387-389) and pre-plasma and plasma cells have been found in the intrathecal 
tissue of SLE patients with CNS involvement(389) and in the synovial tissue of patients with 
rheumatoid arthritis(193).  Plasma cells were found to accumulate and reside in the inflamed 
kidneys of autoimmune NZB/W mice(382), and several studies suggest B cells can infiltrate 
the kidney and contribute to glomerulonephritis in SLE(390, 391).  Studies of the synovium 
of RA patients and in the CNS during viral infection strongly support a vital role for the 
interaction of CXCR3 on B cells and CXCR3 ligand expression in these tissues for 
recruitment and retention of plasma cells(193, 195).  Thus, we propose that inflamed tissue is 
the final destination for CD19hi B cells.    
The elevated expression of CXCR3 and responsiveness to its ligand CXCL9 suggests 
a possible mechanism for the increased incidences of ESRD and severe neurological 
dysfunction in CD19hi Pts.  We speculate that some CD19hi cells are homing to the kidney 
and CNS where they clonally expand and differentiate to plasma cells.  Interestingly, a 
previous study found an association between a positive anti-Sm titer and CNS involvement in 
SLE(392).  Our data suggests that this association may be secondary to an expansion of 
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CD19hi B cells, since such an expansion correlates with an elevated anti-Sm titer.  The 
pathology resulting from the migration of CD19hi cells into peripheral sites of inflammation 
might arise from locally high concentrations of autoantibodies.  However, B cells can 
contribute to pathology through mechanisms independent of antibody production, such as 
production of cytokines and activation of T cells.  As mentioned above, the exponential 
association between enrichment of anti-Sm cells in the CD19hi compartment and the serum 
anti-Sm titer strongly suggests that such additional mechanisms are taking place.  Thus, the 
presence of pre-plasma cells in these sites may be important for providing signals to other 
effectors of inflammation.   
The presence of CD19hi B cells in a subset of SLE patients may have implications for 
prognosis and treatment.  Although rituximab is a promising new therapy for SLE, not all 
patients have a robust clinical response.  This may be because not all B cell subsets are 
equally susceptible to depletion.  While PB B cells and follicular B cells are depleted 
efficiently, marginal zone and memory B cells are less responsive to depletion, and plasma 
cells, which do not express CD20, are not depleted at all(315, 393).  We do not yet know 
how susceptible the CD19hi B cells are to rituximab depletion, but our data suggest that 
CD19hi patients are poor clinical responders to rituximab.  This finding further differentiates 
CD19hi patients as a distinct subgroup of SLE patients and provides a predictive test for 
clinical response to rituximab.  Sanz and colleagues have recently shown that SLE patients 
with high titers of antibodies to Sm, snRNP, Ro, and La have decreased responsiveness to 
rituximab(367).  This is consistent with the findings reported here, since the presence of 
CD19hi B cells is associated with elevated titers of antibodies to Sm and other snRNP 
antigens, although anti-Ro antibodies were found to be lower in CD19hi patients(365).   
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Given the increase in adverse outcomes in these patients, it will be important to determine 
more efficacious therapies for treatment of their disease. Anti-CXCR3 therapy is currently 
under development for multiple inflammatory diseases, and we surmise that this may be a 
prudent choice for treatment of CD19hi patients. 
Taken together, the data presented here and previously by this lab(365) suggest that 
the presence of CD19hi cells delineates a subgroup of SLE Pts with increased adverse clinical 
outcomes, a specific pattern of autoreactivity, and decreased response to Rituximab 
treatment.  Separating heterogeneous diseases, such as SLE, into etiological and pathological 
subgroups is vital to developing appropriate therapeutic modalities and improving clinical 
outcomes.
111
Table 3.1. Clinical outcomes of CD19hi and CD19lo Pts. 
Outcome CD19lo Pts CD19hi Pts P vaule 
Severe Neurologic 0% (0/27) 29% (4/14) 0.01 
ESRD 4% (1.27) 29% (4/14) 0.04 
TTP 7% (2/27) 7% (1/14) >0.05 
Death 4% (1/27) 14% (2/14) >0.05 
Any Adverse 15% (4/27) 64% (9/14) 0.003 
27 CD19lo and 14 CD19hi Pts were followed over five years for occurrence of four clinical 
sequelae of SLE.  Fisher’s exact test was used to determine significance of a 2x2 contingency 
table for each outcome.  ESRD, end stage renal disease. TTP, thrombotic thrombocytopenic 
purpura. 
 
Table 3.2. CD19hi cells are not in S phase. 
Fold Ki-67 in CD19hi 
vs CD19lo B cells 
% PI high in 
CD19hi B cells 
% PI high in 
CD19lo B cells
Patient 1 1.78 2.3% 2.8% 
Patient 2 1.72 3.0% 3.5% 
Patient 3 1.54 2.0% 2.0% 
The fold increase in the MFI for Ki-67 staining in CD19hi vs CD19lo B cells from the same 
patient, as well as percentage of each population falling into a PI high gate, indicating S 
phase. 
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Figure 3.1. CD19hi Pts are poor responders to Rituximab treatment.   
Clinical response of CD19hi SLE Pts and CD19lo SLE Pts to Rituximab treatment. NR=no 
response; OG=ongoing response. 
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Figure 3.2. CD19hi cells are enriched for autoreactivity, and the degree of autoreactivity 
in these cells correlates exponentially with serum autoantibody.   
CD19hi and CD19lo cells were sorted from four Pts with differing anti-Sm titers, and ELISpot 
used to determine the number of anti-Sm ASCs in each group. A, Anti-Sm ASCs per million 
CD19hi or CD19lo cells in each of four Pts. Pt 1 did not have detectable serum anti-Sm titer, 
and no anti-Sm ASCs were seen in either cell group. B, Anti-Sm ASCs per million cells in 
each group vs. log10[anti-Sm serum titer], showing an exponential relationship between the 
number of anti-Sm ASCs in the CD19hi cell group and the serum titer of anti-Sm. 
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Figure 3.3. Basal phosphorylative state of CD19hi cells.   
PB cells were permeabilized and stained using antibodies recognizing the indicated 
molecules.  A, Fold increase in MFIs of CD19 or phosphorylated CD19 (pCD19) in CD19hi 
vs CD19lo cells.  B, Representative histograms of PB cells from a CD19hi Pt and HC stained 
for CD19 and pSyk, pERK1/2, or an isotype control.  C, Representative single parameter 
histograms showing staining for phosphorylated or total Syk and ERK1/2 in PB from a HC 
(shaded) and CD19lo (thin line) and CD19hi (thick line) B cells from the same Pt.  D, Fold 
increases in MFI for the labeled signaling molecules in CD19lo vs. CD19hi cells from the 
same Pt.  Each dot represents a different Pt and/or day.  At least four different Pts are 
included for each signaling molecule. Significance for single molecules was determined 
using a 2-sided non parametric rank test.  Significance for pCD19/CD19, pSyk/Syk and 
pERK1/2/ERK comparisons was determined using 2-sided Wilcoxon rank-sum tests. 
*p<0.05, **p<0.01. 
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Figure 3.3, continued.
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Figure 3.4. CD19hi cells respond to BCR crosslinking.   
A, Representative histograms of PB B cells from a CD19hi Pt and a HC after incubation with 
media alone or with -IgG for 10 min.  Percentages indicate percent of B cells falling into 
each gate.  B, Representative single parameter histograms for each of the indicated 
phosphorylated molecules in PB B cells from a HC and CD19lo and CD19hi cells from a Pt 
after incubation with media (shaded) or pansorbin (line) for 10 minutes.  C, Fold change in 
the percentage of cells falling into the positive gate for each of the phosphorylated signaling 
molecules tested in cells incubated with media or pansorbin in a HC or in CD19lo and CD19hi 
cells from the same Pt.  Each point represents a different individual with at least four per 
group.  Significance was determined by Kruskal-Wallis tests. *p<0.05, **p<0.01.  D, CD19hi 
and CD19lo cells were sorted and IgG antibody secreting cells (ASCs) determined after 
incubation with either media alone or with pansorbin, anti-CD40, IL-10 and IL-2 for 6 days. 
Each dot represents a different Pt. 
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Figure 3.4.
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Figure 3.4, continued.
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Figure 3.4, continued.
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Figure 3.4, continued.
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Figure 3.5. CD21 expression is downregulated in CD19hi cells, and sCD21 is decreased 
in the serum of CD19hi Pts.   
A, Surface expression of CD21 as determined by flow cytometry. Histogram is representative 
of more than 5 Pts.  B, CD21 transcript levels as determined by RT-PCR. CD19lo and CD19hi 
cells were sorted from three Pts and the expression of CD21 transcripts in CD19hi cells 
determined relative to expression in CD19lo cells from the same Pt.  C, sCD21 levels in the 
serum of SLE Pts with and without a positive Sm titer and in HC as determined by ELISA. 
Significance determined by student’s t test. **p<0.01. 
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Figure 3.6. CD19hi cells appear to be pre-plasma cells.   
A and B, Transcription factor expression in indicated sorted B cell groups as determined by 
RQ RT-PCR.  Each bar represents a different individual.  A, Relative expression in CD19hi 
cells as compared to CD19lo cells from the same patient.  B, Relative expression in 
CD19+CD38-IgD- memory cells as compared to all other CD19+ cells from the same HC.  
A, Representative histograms for Ki-67 staining in non-lymphoid PBMCs (shaded) and 
CD19lo (thin line) or CD19hi (thick line) Pt PB B cells and for PI staining of indicated 
subsets.  Percentages indicate cells falling into drawn gate.  
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Figure 3.6, continued.
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Figure 3.7. CXCR expression in CD19hi and HC memory cells.  
A and B, CXCR expression in indicated sorted B cell groups as determined by RQ RT-PCR.  
Each bar represents a different individual.  A, Relative expression in CD19hi cells as 
compared to CD19lo cells from the same patient.  B, Relative expression in CD19+CD38-
IgD- memory cells as compared to all other CD19+ cells from the same HC.  C, Surface 
CXCR3 expression determined by flow cytometry in a HC (shaded) or in CD19lo (thin line) 
or CD19hi (thick line) cells from the same Pt.  Histogram is representative of three patients.  
D, Chemotaxis of CD19hi cells in response to the CXCR3 ligand CXCL9, the CXCR4 ligand 
CXCL12, or media alone.  Migration was determined by collection and staining of cells in 
upper and lower wells after 90 minutes. 
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Figure 3.7, continued.
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CHAPTER 4: GENERAL CONCLUSIONS AND FUTURE 
DIRECTIONS 
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Autoimmune disease remains a mysterious realm in medicine.  Though we continue 
to progress in our understanding of these devastating diseases, we still do not understand 
most aspects of their etiology or pathology.  Because of this, we cannot cure these diseases, 
and must rely on palliative treatments which carry significant morbidities of their own. 
 SLE is often thought of as a general model for systemic autoimmune diseases.  It is 
one of the most severe, and can affect essentially every organ system in the body.  Also like 
other autoimmune diseases, its etiology has significant environmental and genetic 
components.  Interestingly, even though some of these causes have been identified, how and 
why they contribute to the development of SLE is unknown. 
 The “two hit” hypothesis has been proposed to explain the complicated nature of the 
etiology of autoimmune disease.  This hypothesis states that most of the time, a single 
genetic polymorphism or abnormality, or environmental exposure, may predispose to 
development of autoimmunity, but cannot alone lead to its development.  A second “hit”—
that is, a polymorphism in another gene that also predisposes to disease, or a specific 
environmental exposure at the appropriate time—must also be present to develop 
autoimmune disease. 
 For example, Epstein-Barr virus (EBV), although present in >80% of the general 
population, has been associated with SLE(272, 347).  Clearly, EBV infection alone does not 
break self-tolerance; it must enter into a system predisposed to autoimmunity.  In addition, 
none of the genetic polymorphisms that have been associated with SLE always result in 
disease.  It is because of these complex and multi-parameter interactions that understanding 
of autoimmunity is still beyond our grasp. 
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Another impediment to our understanding of SLE is that, although it is heterogeneous 
in its etiology and pathogenesis, only one clinical diagnosis exists.  An examination of even 
the simplified diagnostic criteria listed in Table 1.5 is enough to highlight how many varying 
symptoms in different combinations are diagnosed as SLE.  The fact that we are most likely 
artificially grouping several diseases with distinct causes and pathology under a single 
diagnosis makes it more difficult to find the correct and relevant associations with genes and 
environmental exposures needed to understand SLE.  For example, if all patients with a 
genetic alteration of FcR2b were categorized as having “Type 1” SLE instead of lumped 
together with all patients diagnosed with SLE, then there would be a perfect concordance of 
“Type 1” SLE and FcR2b mutations. 
The lack of clinical or pathological delineation between putative subgroups of SLE 
impairs not only our understanding of this disease, but also our ability to effectively treat 
SLE patients.  On the other hand, findings that are very common among all patients are 
useful in that they may enable developing treatments which have wide-spread efficacy.  
Herein I have presented data which links seemingly disparate autoimmune diseases and 
patients within these groups, as well as data which separates SLE patients into potential 
disease subgroups.   
We have found that CD19 is decreased on peripheral B cells from a vast majority of 
patients with SLE or ANCA-SVV.  This finding is very surprising, given the above 
discussion of heterogeneity within these diseases.  In addition, the CD19 locus has been 
closely examined for polymorphisms which might be associated with autoimmune disease 
without much success. One study found an association with two CD19 polymorphisms and 
systemic sclerosis, although these resulted in increased CD19 expression and conferred odds 
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ratios of only ~2(351). Another study found a ~2-fold increased prevalence of a 
polymorphism in the 3’ UTR of CD19, resulting in slightly decreased CD19 expression, in 
Japanese SLE patients(350), although this has not been successfully repeated in any other 
patient groups.  A group of patients with hypogammaglobulinemia and immune deficiency as 
a result of a homozygous CD19 mutation resulting in complete lack of CD19 expression has 
also been described(394).  As predicted, based on findings from CD19 deficient mice, these 
patients were immunodeficient, and did not have circulating autoantibody nor develop 
autoimmunity. No other associations between genetic polymorphisms of CD19 and human 
disease have been found, and none of these studies can explain the finding of decreased 
CD19 expression in >95% of SLE and ANCA-SVV patients. 
It therefore seems most likely that CD19 expression is decreased on these cells as a 
consequence of disease pathology, rather than as a cause of it.  In fact, we have generated 
preliminary data which suggests that soluble factors secreted by PBMCs from SLE patients 
are able to decrease CD19 expression on B cells from both patients and healthy controls.  
However, regardless of whether low CD19 expression is a cause or consequence of disease, it 
may have implications for perpetuation of disease.  If decreased CD19 expression is present 
in immature or transitional B cells, it could inhibit negative selection of these cells, allowing 
escape of autoreactive specificities into the mature, functional B cell pool.  Therefore, further 
investigation into the mechanism responsible for decreased CD19 expression in these 
diseases may provide new avenues for treatment. 
The first step would be to verify the presence of a secreted factor or factors which are 
able to downregulate CD19 expression. Next would be to identify the cytokines and to 
determine the mechanism by which they decrease CD19 expression. These studies could be 
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carried out in several ways. Cytokine arrays could be used to compare the supernatants of 
PBMCs from SLE patients and healthy controls.  Any cytokines with higher concentration in 
SLE PBMC supernatant compared to healthy control PBMC supernatant would be possible 
candidates.  Clues as to the identity of these candidates would also be found in the literature 
describing cytokines found at increased concentration in the sera of SLE patients, such as IL-
6, IL-10 and BAFF.  These candidate cytokines could then be depleted from supernatants or 
blocked using monoclonal antibodies to determine which affects CD19 expression.  Once the 
culprit is determined, the mechanism by which it accomplishes CD19 downregulation can be 
addressed using standard molecular biology techniques and phosflow staining to dissect 
signaling pathways.  Identification of the players involved in this process would provide drug 
targets for adjunctive therapy in SLE. 
We have also shown that patients with an expanded CD19hi memory B cell 
population may comprise a distinct subset of SLE patients.  CD19hi patients differ from 
CD19lo patients in several ways.  They have a unique pattern of autoreactivity, as shown in 
Figure 2.7.  They also have an increase in adverse outcomes, particularly ESRD and severe 
neurological outcomes (Table 3.1).  Finally, and unfortunately, show poor clinical response 
to rituximab treatment (Fig. 3.7).  Taken together, these findings suggest that CD19hi cells in 
the PB can be used as a marker for SLE patients at high risk for ESRD, neurological 
dysfunction, and overall adverse outcomes, and that rituximab alone is not likely to be an 
effective therapy for these patients. 
CD19hi B cells appear to be a functionally and phenotypically distinct, autoreactive 
subset of memory B cells.  Several recent studies have implicated the memory B cell 
population to be important in autoimmune disease(201, 266, 307), and our data support this 
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idea.  We do not yet know whether CD19hi cells are newly generated memory B cells or 
memory B cells that have undergone a single or multiple rounds of reactivation.  This may be 
a difficult question to address, although employing the IgG sequencing techniques outlined in 
Chapter 2 to following the CD19hi clones in several patients over time might provide insight.  
If a limited set of clones are consistently present over time in a single patient, this would 
argue strongly for continued re-activation of a relatively constricted initial pool of memory 
cells.  A constantly expanding number of clones would suggest that CD19hi memory B cells 
are being continually generated, and are newly emerged germinal center reactions. 
CD19hi memory B cells are similar to non-CD19hi memory B cells in their 
downregulation of CD38 and in the expression of mutant IgG BCRs.  However, they differ in 
their decreased expression of CD27, CD21, and Pax-5 and their increased expression of 
CD19, CD20, and CXCR3.  An important next step in the study of these cells would be to 
conduct a more thorough comparison of gene expression between these two groups, such as 
the employ of a gene chip analysis.  In addition to determining the extent of their differences, 
this kind of analysis may also provide unique surface markers which could make future 
studies, such as the immunohistochemistry analysis of peripheral tissue, possible. 
CD19hi cells have a unique basal phosphorylative state, with increased basal 
phosphorylation of Syk and ERK1/2 but not CD19, Akt, p38 or JNK.  Further exploration of 
functional and signaling alterations in these cells may provide the key to developing 
therapies for CD19hi patients.  Unfortunately, further studies of signaling in CD19hi cells are 
greatly impaired by the number of B cells that can be acquired.  The maximum number of B 
cells that can be purified from a single patient is in the range of 2-3x105 cells, far too few for 
western blot analysis.  Therefore, we must rely on examination by flow cytometry and are 
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consequently limited by availability of antibodies and reagents which are compatible with 
this technique.  For example, it would be useful to measure phosphorylative stages of 
molecules upstream of Syk, such as Lyn, and between Syk and ERK1/2 activation, such as 
Ras and Raf; unfortunately, antibodies that recognize these molecules are not currently 
available for use in flow cytometry.  As this method gains favor, however, antibodies 
recognizing a wider variety of phosphorylated signaling molecules will be developed for this 
purpose and the mechanisms at work here can be further defined. 
We have shown that CD19hi B cells are not anergic, despite their increase in 
autoreactive specificities.  They phosphorylate CD19, Akt, p38 and JNK normally in 
response to stimulation with pansorbin and are able to differentiate to ASCs with pansorbin, 
anti-CD40, IL-10 and IL-4 stimulation.  A logical next step would be to examine the 
proliferative potential of these cells in response to various stimuli.  In addition, it will be 
important to further explore the response of these cells to other stimuli, particularly TLR 
ligands and BAFF, both of which have been implicated in autoimmunity.  It would be 
interesting to know the minimum stimulation required to trigger the differentiation of these 
cells to ASCs, as this would give us hints as to how they may be activated in vivo. For 
example, is BCR crosslinking alone enough to generate ASCs in this population?  If so, it 
would seem that they may be activated to become effector cells in the absence of T cell help.  
Alternatively, perhaps they do not require BCR stimulation, and the presence of certain 
cytokines is enough to stimulate differentiation.  This would suggest that these memory B 
cells can be continually activated in a pro-inflammatory environment, even in the absence of 
cognate T cell help or significant antigen.  These studies might also provide reasonable 
therapeutics for blocking the activation of these cells. 
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The presence of CD19hi B cells is associated with increased adverse clinical 
outcomes, particularly neurological dysfunction and ESRD.  Importantly, only Patients with 
a CD19hi population had neurological complications in this study.  We hypothesize that 
CD19hi cells home to peripheral sites of inflammation, particularly to the kidney and the 
CNS, where they mediate multiple effects including local production of autoantibody and 
possibly activation of T cells and other cells of the immune system (Fig. 3.1).  B cells have 
already been shown to have these roles in autoimmune disease(393), and given their 
activated phenotype and high CXCR3 expression, CD19hi B cells seem particularly apt to 
mediate these effects.  In addition, a 2-fold increase in anti-Sm reactive B cells in the CD19hi 
compartment results in a 100-fold increase in serum anti-Sm.  This finding strongly supports 
the ideas that CD19hi B cells (1) are primary producers of serum antibody against certain 
autoantigens, (2) divide prior to differentiating, and (3) play a regulatory role in amplifying 
the immune response towards particular autoantigens, possibly through the activation of 
cognate T cells. 
 These cells may be particularly suited to APC function given their increased surface 
expression of MHCII and CD86.  They have slightly decreased CD40 expression, but in 
many instances signaling by CD154 after interaction with CD40 is dispensable for T cell 
activation, and in some settings it is actually inhibitory(395, 396).  It would therefore be very 
interesting to determine the ability of these cells to activate naïve and memory T cells; 
however, these studies pose some obvious technical difficulties.  Ideally, one would want to 
determine the ability of these B cells to activate T cells for their cognate antigen; however, 
this would require ability to isolate and purify T cells specific for, for example, Sm.  
Currently, this is not feasible.  However, less specific in vitro assays might be employed 
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using CD19hi B cells loaded with Sm and total CD4+ T cells purified from the PB of the 
same patient.  It will also be interesting to determine if these B cells are significant producers 
of cytokines, as has been reported for other B cell subsets in autoimmunity(397). 
 
Figure 4.1. Unifying hypothesis of CD19hi cell activation, homing and effects in 
peripheral sites of inflammation.
CD19hi cells are either reactivated or newly generated memory cells which leave the follicle and 
home to peripheral sites of inflammation.  There they proliferate and differentiate into autoantibody 
secreting cells.  The locally produced autoantibody forms immune complexes which in turn mediate 
inflammatory reactions.  In addition, they activate T cells, which also proliferate and mediate their 
own actions, such as activation of other inflammatory cell types (CD8+ T cells, for example).  
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Though our data support the idea that CD19hi B cells are important to disease 
pathogenesis, the only way to definitively prove this would be to transfer them to a host 
without autoimmunity and show that these recipients then acquire key features of disease.  
Clearly, such a study is not possible.  One similar scenario is to show that features of disease 
are abrogated upon depletion of CD19hi B cells.  If rituximab efficiently depleted these cells, 
one might argue that this approach would be successful.  However, only depletion of CD19hi 
cells in the peripheral blood could be reasonably monitored, and our data suggest that these 
cells may only exist in the PB briefly before homing to sites of inflammation, where they 
would be highly resistant to depletion(393) and difficult to detect.  To prove they have been 
fully depleted, sections of all relevant tissue would have to be examined, and this would be 
impossible in human subjects.  Moreover, it appears that these cells are in fact not efficiently 
depleted by rituximab, although due to the reasons just described, this will be difficult to 
prove. 
A more reasonable and practical approach to further explore our hypothesis would be 
to use immunohistochemistry of tissue sections of inflamed organs or tissues from SLE 
patients, particularly kidney.  If we are correct, CD19+CD21-CXCR3+ and CD19-
CD138+intracellular IgG+CXCR3+ cells should be present in these tissue sections.  Some of 
the CD19+CD21- cells should stain for Ki-67, indicating proliferation.  We should also be 
able to stain for CXCR3 ligands in the endothelial tissue to verify their expression near 
accumulation of CD19+CD21-cells.  If, in the future, medications are available which 
effectively treat CD19hi patients, these might be useful to determine the true role of these 
cells in disease. 
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We do not yet know what percentage of CD19hi cells are autoreactive.  This question 
could be approached in two ways.  First, the ELISpot technique described in Chapter 3 could 
be used to look for reactivity to other autoantigens.  Although most patients with a CD19hi 
population are strongly snRNP reactive and have minimal reactivity to other autoantigens 
(Fig.2.7), some autoantibodies are also seen CD19hi patients, such as anti-dsDNA and anti-
phospholipid antibodies.  Additionally, individual Ig genes could be cloned from single-cell 
sorted CD19hi B cells, expressed in culture, and their specificity determined, using techniques 
recently described(201).  It would be especially useful to determine if the exponential 
relationship between enrichment and serum autoantibody titer seen in the case of Sm is 
consistent for other autoantigens. 
CD19hi patients do not have a robust clinical to rituximab, but their increased adverse 
outcomes dictate a particular need for treatment options.  Given the high CXCR3 expression 
on CD19hi B cells, we propose that anti-CXCR3 treatment may be an efficacious treatment 
for these patients. Numerous lines of data suggest that blocking CXCR3 interactions with its 
ligands may abrogate disease in CD19hi patients, as discussed in Chapter 3. These studies 
support the idea that CXCR3+ B cells can migrate to sites of inflammation, where, among 
other effector functions, they can differentiate into PCs. Therefore, blocking CXCR3 would 
prevent the migration of autoreactive CD19hi B cells into peripheral sites of inflammation, 
and may deny them a niche in which to differentiate to PCs and block their local effector 
functions(393).   
In addition, a synergistic effect has been seen using rituximab together with blockade 
of BAFF(393).  This approach may be helpful in the treatment of CD19hi patients, however, 
we have found that BAFF Receptor 3 (BR3) expression is consistently decreased on CD19hi 
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cells, suggesting that these cells may have become BAFF-independent.  To further explore 
this idea, levels of the other two BAFF receptors, TACI and BCMA, must be determined.  In 
addition, effects of BAFF on these cells could be determined by examining survival ex vivo 
in the presence and absence of BAFF. 
An overarching and necessary follow-up for the studies described in this dissertation 
would be to examine a much larger cohort of patients to further delineate and verify clinical 
and pathological differences, as well as differences in response to various treatments, in 
CD19hi SLE patients vs. SLE patients without an expanded CD19hi population.  As SLE has 
always been thought of as a heterogeneous disease, studies such as these which begin to 
separate apparent disease subtypes are vital to developing individualized, and therefore more 
efficacious and less debilitating, therapeutic modalities.  
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